WO2006116392A2 - Particle-containing complex porous materials - Google Patents
Particle-containing complex porous materials Download PDFInfo
- Publication number
- WO2006116392A2 WO2006116392A2 PCT/US2006/015612 US2006015612W WO2006116392A2 WO 2006116392 A2 WO2006116392 A2 WO 2006116392A2 US 2006015612 W US2006015612 W US 2006015612W WO 2006116392 A2 WO2006116392 A2 WO 2006116392A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particles
- nano
- materials
- micro
- porous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
Definitions
- the present disclosure relates generally to controlled release therapeutic materials, and more particularly to such materials formed from particle-containing complex porous materials.
- Controlled release of biologically active agents using polymeric materials is a powerful means for a wide variety of therapeutics.
- Such approaches may be especially advantageous for delivery of therapeutic agents to a localized area to substantially circumvent unwanted systemic side effects, to achieve high local dosages without the use of large quantities of therapeutic agents, and/or to prevent unnecessary destruction or denaturing of the agents in the delivery routes (such as in circulation or the gastrointestinal track).
- tissue engineering/regenerative medicine is another interdisciplinary and multidisciplinary field, which aims to generate biological replacements for damaged tissues, failing organs, and dysfunctional body parts. Still young and growing, the field significantly challenges the current treatment modalities represented by transplantation, surgical reconstruction, and the usage of prostheses, each of which has inherent limitations.
- an artificial temporary extracellular matrix (a.k.a. scaffold) plays an important role as a 3D guidance for cell adhesion, proliferation, and new tissue organization.
- These scaffold materials are compatible with cells and biological host environments.
- Such scaffolds also possess the appropriate porous structure suitable for cell penetration, nutrient supplies, and metabolic waste removal. Desirably, they may also encourage needed cell-cell and cell-matrix interactions; and may be biodegradable to eventually fade away after fulfilling the purpose as templates (as this may obviate long-term foreign body reactions and associated complications).
- biological signaling may also be necessary for cell function and tissue regeneration.
- Endogenous signaling molecules are often not sufficient in quantities or types for regeneration purposes, where the addition of signaling molecules is desirable.
- stem cells when stem cells are used for regeneration, the lineage control often relies on the use of differentiation factors.
- addition of biological molecules in a culture medium either in a continuous or discrete fashion is often possible.
- such addition of factors to a cell-scaffold construct or regenerating tissue may be very challenging, if not virtually impossible. Due to the sensitivity of cells to the concentration of biological molecules and because of the short half-lives of many of these agents, controlled release technologies are being introduced into the field of tissue engineering and regenerative medicine.
- tissue engineering scaffolds Many controlled release techniques may potentially be introduced into tissue engineering scaffolds. Those that are relatively easy to adapt have been recently utilized for tissue engineering applications. For example, hydrogels have been used as both drug delivery matrices and tissue engineering scaffolds. Further, growth factors, along with cells, have been incorporated into hydrogel scaffolds to enhance regeneration.
- biological agents have also been directly added into a polymer or a blend of polymers, and the mixture is then used to fabricate a scaffold.
- ascorbate-2- phosphate and dexamethasone (AsAP and Dex, agents to enhance osteoblastic differentiation of cells) have been mixed in chloroform, which was used to dissolve poly(d,l- lactide-co-glycolide) (PLGA). This resulted in a mixture (Dex and AsAP suspended in a PLGA solution).
- This polymer suspension was mixed with salt particles to fabricate a scaffold using the salt-leaching technique, i.e., after the evaporation of solvent, the salt particles were leached away by water to form pores.
- PLLA-PDGF platelet derived growth factor
- PLGA-bFGF basic fibroblast growth factor
- bFGF hepatocyte growth factor
- PDGF-BB vascular endothelial growth factor
- IGF-I insulin like growth factor- 1
- Porous bioglass materials have been coated with a laminin solution to allow for subsequent slow release.
- An emulsion of a polymer solution and vitamin B 12 solution has been used to coat certain porous polymer materials.
- Basic fibroblast growth factor (bFGF) was complexed with sucralfate and polyHEMA and then coated on PLLA scaffolds to enhance liver tissue formation.
- bioactive agent incorporation may, in some instances, achieve certain slow release purposes, but the control over release profile of a bioactive agent is generally limited. Further, these methods are not suitable for releasing multiple agents with individualized controlled release profiles.
- micro- and/or nano-spheres or particles also referred to herein as "MNS” and/or “MNP”, these abbreviations meaning herein, micro- spheresAparticles, nano-spheres/-particles, or combinations thereof
- polymers often biodegradable polymers
- Attempts are also being made to incorporate the controlled release capacity into scaffolding materials to provide desired bioactive agents.
- the successful realization of such ideas to date has proven technically challenging.
- MNS/MNP containing transforming growth factors TGF- ⁇ i
- TGF- ⁇ i transforming growth factors
- Gelatin MNS/MNP containing bFGF have been mixed with preadipocytes and dripped on collagen sponge sheets to engineer adipose tissue.
- this method is limited because the added MNS/MSP may migrate under gravity, physical motion, mechanical interference (stirring, shaking, mechanical stress and so forth), and/or fluid flow. Such migrations may deleteriously lead to undesired distribution or loss of MNS/MNP.
- PLGA MNS/MNP encapsulating IGF-I (insulin-like growth factor) and TGF-P 1 have been entrapped together with condrocytes in a photopolymerized PEO (polyethylene oxide) hydrogel for cartilage formation.
- Advantages of such in situ gelling systems include the ability to fill irregularly shaped tissue defects, allowing minimally invasive procedures (such as injection and arthroscopic surgery), and the ease of cell and MNS/MNP incorporation.
- the disadvantages include the non-degradability of PEO, the lack of control over macro- and micro-pore shape and size in the gels, and poor mechanical properties.
- bFGF-containing PLGA MNS/MNP have been incorporated into alginate gel and crosslinked.
- the alginate gel was then lyophilized to form solid porous materials as a membrane to release bFGF for enhanced angiogenesis and wound healing.
- the advantage of this method is that the solid-state form may be more mechanically stable than gels.
- the disadvantages include the lack of matrix degradability (alginate), the inability of controlling pore shape, and the limited ability of varying pore size.
- calcium-phosphate cement was also loaded with PLGA MNS/MNP to release rhBMP-2 (recombinant human bone morphogenetic protein-2).
- this system generally has similar disadvantages such as the lack of degradability, and the inability of controlling pore shape and pore size.
- Another method of entrapping PLGA MNS/MNP into a porous scaffold is gas foaming.
- carbon dioxide (CO 2 ) is usually used as a foaming agent. Solid polymer disks are exposed to high pressure CO 2 to allow saturation of CO 2 in the polymer. Thermodynamic instability is then created by rapidly releasing CO 2 gas from the polymer system, followed by the nucleation and growth of gas bubbles in the material.
- This method allows protein or DNA powders or PLGA MNS/MNP to be entrapped in the materials.
- the disadvantages of this method include the lack of control over pore size and shape, and a nonporous surface, closed-pore structure, with only between about 10% and about 30% of interconnected pores.
- the porosity and interpore connectivity may, in some instances, be improved by combining salt-leaching techniques with the gas foaming process, although eliminating closed pores has yet to be successfully achieved. Additionally, the leaching process may remove a large portion of the incorporated agents in an uncontrolled manner, which is also not desirable. Furthermore, the embedded MNS/MNP in the walls of the porous materials generally lose the desired release profiles of the MNS/MNP.
- PLGA MNS/MNP have been coated with a layer of PVA (polyvinyl alcohol).
- PVA polyvinyl alcohol
- the PLGA solution with suspended PVA-coated MNS/MNP was used with salt particles to fabricate scaffolds based on salt-leaching techniques.
- the PVA coating does not dissolve in organic solvents such as THF (tetrahydrofuran), thereby potentially preventing the dissolution of PLGA MNS/MNP in a PLGA solution.
- THF tetrahydrofuran
- Porous materials and methods for forming the same are disclosed.
- One of several methods disclosed herein for immobilizing at least one of micro-particles and nano-particles onto internal pore surfaces and/or external pore surfaces of porous materials includes suspending the micro-particles and/or nano-particles in a liquid adapted to swell, soften, and/or deform either the porous materials and/or the particles, thereby forming a liquid- particle suspension.
- the method further includes adding the suspension to the porous materials; and removing the liquid, thereby forming the porous materials having the micro- particles and/or nano-particles immobilized on the internal pore surfaces and/or the external pore surfaces.
- Fig. IA is a scanning electron micrograph (SEM) of PLGA50-64K microspheres
- Fig. 2A is a SEM of a PLLA nano-fibrous scaffold at low magnification of 10OX, showing well-interconnected macropores and inter-pore openings;
- Fig. 2B is a SEM of a PLLA nano-fibrous scaffold at high magnification of 10,00OX, showing nano-fibrous pore wall surfaces;
- Figs. 3 A and 3B are each SEMs of PLLA microporous/solid scaffolds, showing a PLLA macroporous scaffold with microporous pore wall structures;
- Figs. 3 C and 3D are each SEMs of PLLA microporous/solid scaffolds, showing a PLLA macroporous scaffold with solid pore wall structures;
- Figs. 4A and 4B are each SEMs of PLLA nano-fibrous scaffolds post seeded with
- PLGA microspheres showing well maintained macroporous and nano-fibrous scaffolds incorporated with about 1.6 mg PLGA50-64K MS;
- Fig. 4C is a SEM of PLLA nano-fibrous scaffolds post seeded with PLGA microspheres, showing well maintained macroporous and nano-fibrous scaffolds incorporated with about 0.16 mg PLGA50-64K MS;
- Fig. 4D is a Laser scanning confocal micrograph at 200X of a microsphere- incorporated nano-fibrous PLLA scaffold, post-seeded with TRITC-BSA/PLGA50-6.5K (red) and FITC-BSA/PLGA50-64K (green) microspheres;
- Fig. 4E is a Laser scanning confocal micrograph at 200X of a microsphere- incorporated nano-fibrous PLLA scaffold post-seeded with PLGA50-64K microspheres encapsulating TRITC-BSA (red) and FITC-dextran (green);
- Figs. 5A and 5B are each SEMs of PLLA microporous/solid scaffolds post-seeded with PLGA microspheres;
- Figs. 5C and 5D are each SEMs of microsphere-incorporated solid-walled PLLA scaffold;
- Fig. 5E is a SEM of microsphere-incorporated in a solid- walled PLGA85 scaffold;
- Fig. 6A is a SEM of a PLGA50-64K microsphere-incorporated PLLA nano-fibrous scaffold without solvent/non-solvent treatment;
- Fig. 6B is a SEM of a PLGA50-64K microsphere-incorporated PLLA nano-fibrous scaffold treated with 80 ⁇ l hexane/THF (90/10, v/v);
- Fig. 6C is a SEM of a PLGA50-64K microsphere-incorporated PLLA nano-fibrous scaffold treated with ethanol/acetone (90/10, v/v);
- Fig. 7A is a Laser scanning confocal micrograph at 200X of PLLA nano-fibrous scaffolds pre-seeded with TRITC-BSA/PLGA50-6.5K (red) and FITC-BSA/PLGA50-64K (green) microspheres;
- Fig. 7B is a SEM of a PLLA nano-fibrous scaffold pre-seeded with PLGA microspheres
- Fig. 8A is a SEM of chitosan/gelatin microspheres
- Fig. 9A is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold pre-seeded with FITC-BSA-CG (chitosan/gelatin) (green) microspheres and post-seeded with TRITC-BSA/PLGA50-6.5K (red);
- Fig. 9B is a SEM of CG microsphere pre-seeded PLLA nano-fibrous scaffold
- Fig. 1OA is a SEM of chitosan/gelatin (CG) microsphere incorporated PLLA scaffold prepared by PLLA/THF phase separation at -20 0 C;
- Fig. 1OB is a SEM of chitosan/gelatin (CG) microsphere incorporated PLLA scaffold prepared by PLLA/dioxane phase separation at -20 0 C;
- Fig. 12 A is a degradation characterization of PLGA microspheres after post-seeded into PLLA nano-fibrous scaffold using scanning electron microscopy at 10,000X, PLGA50- 6.5K at O, 3, 7, 21 days;
- Fig. 12B is a degradation characterization of PLGA microspheres after post-seeded into PLLA nano-fibrous scaffold using scanning electron microscopy at 10,00OX, PLGA50- 64K at 0, 10, 21, 35 days;
- Fig. 12C is a degradation characterization of PLGA microspheres after post-seeded into PLLA nano-fibrous scaffold using scanning electron microscopy at 10,000X, PLGA75- 113K at 0, 21, 35, 56 days;
- Fig. 13 is a graph depicting release of FITC-BSA from PLGA microspheres in PBS;
- Fig. 14A is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold post-seeded with AF350-BSA/PLGA75-113K microspheres (blue);
- Fig. 14B is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold post-seeded with FITC-BSA/PLGA50-64K microspheres (green);
- Fig. 14C is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold post-seeded with TRITC-BSA/PLGA50-6.5K microspheres (red);
- Fig. 14D is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold post-seeded with a combination of the three types of microspheres from Figs. 14A - 14C;
- Fig. 14E is a graph depicting multiple protein release profiles from microsphere- incorporated nano-fibrous scaffold (TRITC/PLGA50-6.5K, FITC/PLGA50-64K and AF350/PLGA75-113K);
- Fig. 15A is a graph depicting dual release profiles from microsphere-incorporated nano-fibrous scaffolds post-seeded with TRITC-BSA/PLGA50-6.5K and FITC- BSA/PLGA50-64K microspheres;
- Fig. 15B is a graph depicting dual release profiles from microsphere-incorporated nano-fibrous scaffolds post-seeded with PLGA50-64K microspheres of TRITC-BSA and FITC-dextran
- Fig. 15C is a graph depicting dual release profiles from microsphere-incorporated nano-fibrous scaffolds pre-seeded with TRITC-BSA/PLGA50-6.5K and FITC- BSA/PLGA75-113K microspheres;
- Fig. 15D is a graph depicting dual release profiles from microsphere-incorporated nano-fibrous scaffolds pre-seeded with FITC-BSA/CG and post-seeded with TRITC- BSA/PLGA50-6.5K microspheres.
- compositions incorporating micro-particles/spheres ranging from about 10 " m to about 10 "3 m in dimension
- nano-particles/spheres ranging from about 10 " m to about 10 " m in dimension
- Such complex porous materials allow for the release of various agents in a controlled fashion.
- the present methods and/or compositions substantially, advantageously overcome various limitations of the technologies described hereinabove.
- the materials of the particles and/or porous foam material(s) may be any natural or synthetic materials; organic materials, inorganic materials, metallic materials, composites thereof, and/or combinations thereof.
- the materials are organic materials. They may be natural or synthetic macromolecules.
- the materials are at least one of polymers, proteins, carbohydrates, lipids, and combinations thereof.
- non-degradable polymers include, but are not limited to water insoluble (hydrophobic) polymers/macromolecules that are suitable include polytetrafiuoroethylene (PTFE), polyvinylchloride (PVC), polyethylenes (PE), polypropylenes (PP), polystyrenes, polyacrylonitrile (PAN), polymethylmethacrylate (PMMA), polyvinylacetate (PVAc), polyphenylene oxide, polypropylene oxide (PPO), polyvinylidene fluoride (PVDF), polybutylene, polyamides (PA, Nylons), polyesters, polycarbonates, polyurethanes, polysiloxanes, polyimides, polyetheretherketone (PEEK), polysulfones, polyethersulphone, cellulose, polysaccharides and their derivatives, and mixtures thereof.
- PTFE polytetrafiuoroethylene
- PVC polyvinylchloride
- PE polyethylenes
- PP polyprop
- some exemplary suitable hydrophobic unsaturated monomers include the following: acrylates, methacrylates (eg. methyl methacrylate), ethylene, propylene, tetra- fluoroethylene, styrene, vinyl chloride, vinylidene chloride, vinyl acetate, acrylonitrile, 2,2- bis[4-(2-hydroxy-3-methacryloyloxy-propyloxy)-phenyl] propane (Bis-GMA), ethyleneglycol dimethacrylate (EGDMA), tri-ethyleneglycol dimethacrylate (TEGDMA), bis(2-methacryly-oxyethyl) ester of isophthalic acid (MEI), bis(2-meth-acrylyoxyethyl) ester of terephthalic acid (MET), bis(2-methacrylyoxyethyl) ester of phthalic acid (MEP), 2,2- bis(4-methacrylyoxy
- Monomers of condensation polymers may also be used to form the porous materials in situ.
- Some exemplary monomer types in this category are diacids and diols (pairs), ⁇ -hydroxy carboxylic acids, lactones, diacids and diamines (pairs), amino acids, lactams, diisocyanates, diols (pairs), and/or combinations thereof.
- Biodegradable polymers and macromolecules may also be used, especially when controlled release properties are desired.
- Some exemplary, non-limitative biodegradable polymers are given here: poly(lactide-co-glycolide) (PLGA), poly(L-lactic acid) (PLLA), poly(D,L-lactic acid) (PDLLA), polyglycolic acid (PGA), polyanhydrides, poly(ortho ethers), poly( ⁇ -caprolactone) (PCL), poly(hydroxy butyrate) (PHB), poly(propylene fumarate) (PPF), polyphosphoesters (PPE), polyphosphazenes, and/or mixtures thereof.
- degradable natural macromolecules typically enzymatically degradable
- collagen typically enzymatically degradable
- Some exemplary, non-limitative water-soluble (hydrophilic) polymers/macromolecules that are suitable materials include polyvinyl alcohol, polyethylene oxide (polyethylene glycol), polymethacrylic acid (PMAA), polyvinyl pyrolidone, polyacrylic acid, poly(lysine), poly(allylamine), poly(ethylenimine), poly(acrylamide), poly(acrylamide-co-arylic acid), poly(acrylamide-co-diallyldimethylammonium chloride), poly(vinyl alcohol), poly(ethylene glycol), polyethylene-block-poly(ethylene glycol), poly(propylene glycol), ⁇ oly(2- hydroxypropyl methacrylate), poly(2-hydroxyethyl methyacrylate), poly(4-hydroxystrene), polyethylene monoalcohol, poly(vinyl alcohol-co-ethylene), poly(styrene-co-allyl alcohol), hydroxyethylcellulose, alginate, pectin, chitin, chi
- Certain such polymers/macromolecules can also be synthesized in situ for the porous materials fabrication.
- suitable acid-containing hydrophilic monomers include the following: monomers containing carboxylic acid: acrylic acid, methacrylic acid, 4-vinylbenzoic acid, crotonic acid, oleic acid, elaidic acid, itaconic acid, maleic acid, fumaric acid, acetylenedicarboxylic acid, tricarbollylic acid, sorbic acid, linoleic acid, linolenic acid, eicosapentenoic acid, other unsaturated carboxylic acids, anhydrides, their derivatives, and mixtures thereof; other organic acids such as sulfonic acid, and/or phosphonic acid replacement of the carboxyl group of the above listed unsaturated carboxylic acids, their derivatives, and mixtures thereof.
- Some exemplary suitable amine- containing hydrophilic monomers include allylmine, 4-vinylaniline, L-lysine, D-lysine, DL- lysine, acrylamide, their derivatives, and mixtures thereof.
- Some exemplary suitable hydroxyl-containing hydrophilic monomers include 2-hydroxypropyl methacrylate, 2- hydroxyethyl methyacrylate, 4-hydroxystrene, ethylene glycol, propylene glycol, poly(ethylene glycol) acrylate, poly(ethylene glycol) methacrylate, their derivatives, and/or mixtures thereof.
- hydrophilic and hydrophobic polymers may be both hydrophilic and hydrophobic (amphiphilic). They could also be used for certain foam or particle preparations, such as those containing acid, amine, hydroxyl, and/or other hydrophilic groups in some or all of their structural units. Many of them are copolymers in some way containing both hydrophilic and hydrophobic moieties.
- the agents incorporated in the controlled release particles can be proteins, hormones, DNA, RNA, nutrients, drugs, other biologically regulating agents, and/or the like. It is to be understood that the agents (molecules, ions, or mixtures thereof) are not limited to applications to stimulate cell adhesion, growth, and tissue regeneration. They may be any drugs, pain suppressors, anti- inflammatory agents, sterilizing agents, contraceptives, pesticides, fertilizers, fragrances, spices and so forth. Furthermore, the agents do not have to be biologically active.
- Some exemplary, non-limitative biologically active agents include bone morphogenetic proteins (such as BMP-2, BMP-3, BMP-4, BMP-6, BMP-7 and so forth), transforming growth factors (TGFs, such as TGF- ⁇ and TGF- ⁇ ), acid fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF, PDGF-BB and so forth), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), nerve growth factor (NGF), insulin, insulin-like growth factors (IGFs), parathyroid hormone (PTH), parathyroid hormone related protein (PTHrP), DNAs that encode various factors including the above listed, double- stranded RNAs (dsRNAs) that interfere (silence)
- TGFs transforming growth factors
- TGFs such as TGF- ⁇ and TGF- ⁇
- aFGF acid fibroblast growth factor
- the methods generally include immobilizing the micro-/nano- spheres/particles onto the surfaces of internal and external pores of the pre-fabricated porous material.
- the micro-/nano-spheres/particles (with or without agents to be released) are suspended in a non-solvent of both the particles and the porous material. The suspension is then added into the porous material.
- the particles After evaporation of the non-solvent, the particles are loosely adhered on the internal and external pore surfaces of the porous material.
- loosely adhered it is meant that the particles could be washed away using a non-solvent of the particles.
- a liquid that swells, deforms, or slightly dissolves either or both of particles and porous material such as a relatively poor solvent, or a mixture of a solvent and a non- solvent of the particles and/or the porous material
- the swelling/deforming/slightly dissolving/softening is meant to mean changes that do not substantially affect the release profiles of the particles and/or porous materials. Significantly swelling, deforming, and/or dissolving would generally affect the release profiles of the incorporated agents.
- the liquid helps the particles to strongly adhere to the internal and external pore surfaces.
- the liquid is removed (via freeze-drying, vacuum drying, evaporation, or exchange with a non-solvent for neither the particles nor the porous material). This will result in a porous material with strongly adhered micro-/nano-particles on the pore surfaces.
- strongly adhered is meant that the particles are not easily washed away using a non-solvent of the particles.
- the porous material is fabricated as the immobilization of the MNS/MNP takes place.
- template materials also called porogens
- a material can be made into a template, or small geometrical (regular or non-regular) elements can be assembled or aggregated into a 3D template.
- the template is the negative replica of the porous material to be fabricated.
- the 3D template can be made using various technologies such as programmed fabrication automatically by a machine (rapid prototyping) or batch by batch manually or semi-manually.
- the geometrical element(s) (one example of which is a sugar sphere) is/are formed via emulsification, solvent extraction, and freeze- or air-drying.
- the template/porogen may be formed of any suitable material, non-limitative examples of which are selected from gelatins, collagen, proteins, polypeptides, carbohydrates, polysaccharides, alginate, chitin, chitosan, pectin, salts, sodium hydroxide, sugars, waxes, naphthalene, natural or synthetic water soluble polymers, natural or synthetic non-water soluble polymers, degradable polymers, non-degradable polymers, partially degradable polymers, or combinations thereof.
- the template/porogen material is a sugar sphere template/porogen is formed by first making individual sugar spheres, and then bonding the spheres together. To form individual spheres, a sugar material is melted to form a liquefied sugar material.
- suitable sugar material e.g., carbohydrates that are aldehyde or ketone derivatives of polyhydric alcohols
- suitable sugar materials include sucrose, maltose, dextrose and fructose.
- L-sugars, D-sugars, or combinations thereof may be used.
- D-fructose is used. The temperature at which the sugar material is melted will depend upon the sugar material selected. For example, a D-fructose material melts at about 120 0 C, when exposed to the heat for about 90 minutes.
- the liquefied sugar is then emulsified with a liquid that does not dissolve the sugar (i.e. a non-solvent to the sugar), one non-limitative example of which is mineral oil.
- a non-solvent to the sugar i.e. a non-solvent to the sugar
- the emulsion is formed at a temperature of about 120 0 C.
- the emulsion is then cooled, for example, in an ice-bath. The cooling results in the solidification of emulsion and the formation of the sugar spheres. Any remaining emulsion mixture (e.g., the non-solvent to the sugar) is discarded, and the sugar spheres may be washed/rinsed in any suitable non- solvent to sugar.
- suitable non-solvent to sugar washing liquids include hexane, cyclohexane, and/or the like, and/or combinations thereof.
- the sugar spheres may then be sieved. Desirable sizes for the individual sugar spheres range from about 20 ⁇ m to about 2 mm. In an alternate embodiment, the sizes range from about 50 ⁇ m to 1 mm; and in a further alternate embodiment, from about 180 ⁇ m to about 600 ⁇ m.
- the individual sugar spheres may be packaged in a container/mold within a substantially non-hydrous environment and treated at a predetermined temperature for a predetermined time, sufficient for the spheres to bond.
- the predetermined temperature and predetermined time may be any as suitable or desired. In a non-limitative example, the predetermined time ranges from about 2 minutes to about 12 hours; and in an alternate embodiment, ranges from about 5 minutes to about 3 hours.
- the predetermined temperature ranges from about room temperature to about 100 0 C; and in an alternate embodiment, ranges from about 35°C to about 60 0 C. In a further alternate embodiment, the predetermined temperature is about 37 0 C.
- the non-hydrous environment is a liquid in which the sugar spheres are contained (e.g. hexane)
- the liquid non-hydrous environment may be removed and the template dried under vacuum.
- the template/porogen may be formed from a predetermined three-dimensional configuration of the material(s) (non-limitative examples of which are described herein).
- the predetermined three-dimensional configuration of the template/porogen may have any desirable shape, size, surface morphology, and/or combinations thereof. It is to be understood that the configuration of the template/porogen may depend, at least in part, on the desired geometry and/or configuration of the porous material to be formed.
- non-limitative examples of the geometrical element shapes include cubic or other geometrically shaped crystals, spheres (e.g., sugar spheres discussed herein), fibers, discs, regular geometric shapes, irregular geometric shapes, and/or combinations thereof.
- a suspension of the micro-/nano-particles (with or without agents to be released) in a liquid (may be a mixture) is added onto such a template to coat the complex 3D surface.
- the liquid is then removed.
- Another liquid such as a polymer solution, suspension, or non-polymer solution or suspension
- Any volatile components are removed from the system (such as a solvent, a non- solvent, or a mixture) to form a complex material that includes the template, the micro- /nano- spheres/particles, and the non- volatile components of system. Removal of the volatile component(s) may be accomplished in any suitable fashion, such as by evaporation, freeze-drying, sublimation, extraction, and/or the like, and/or combinations thereof.
- the template material is then removed via any suitable process (such as, for example, dissolving away in a solvent, melting, degrading, and/or the like, and/or combinations thereof).
- a complex 3D porous material is produced with the immobilized MNS/MNP on the interior surfaces.
- MNS/MNP are suspended in liquids that can swell, soften, partially dissolve, and/or deform the particles and/or the porous material, but does not dissolve the MNS/MNP and material(s) used to make the porous (foam) material.
- the MNS/MNP may be suspended in either the liquid or the solution to form a suspension. The suspension is then cast into a mold or on the template of the porous material. In an embodiment in which the liquid suspension is used, the liquid may be removed, and the particles are left strongly adhered on the internal and external surfaces of the porous material.
- the solvent of the liquid such as a polymer solution or suspension
- the solvent of the liquid may be removed (e.g., via evaporation, vacuum drying, freeze drying, sublimation, or being extracted with a non-solvent of the material), and the MNS/MNP are left entrapped in or on the walls of the formed porous material.
- a non-limitative example of the composition formed from either of these embodiments includes immobilized alginate/chitosan microspheres in PLLA nano-fibrous scaffolds with or without macro-pores.
- any of the embodiments described herein may be formed so that the walls of the porous materials are nano-fibrous (such as those formed using a phase separation technology described in at least some of the examples).
- the nano-fibrous matrix may also be formed via other techniques, such as electrospinning. It is believed that the nano-fibrous materials provide better 3D transport, such as, for example, better diffusion conditions for released agents. As such, the nano-fibrous porous materials may allow additional control over the release profiles of the agents contained in the micro-/nano- spheres/particles.
- the pore size of the porous materials described herein may be designed in the nano-size range (10 ⁇ 9 to 10 "6 m in dimension), micro-size range (10 "6 to 10 "3 m in dimension), macro-size range (10 "3 m or larger in dimension), or multiple size ranges, although some preferred size ranges are the nano-size, micro-size, the lower end of the macro-size (10 "3 to 10 “2 m), and/or combinations thereof.
- the porosity of the porous materials may be 30% or higher, preferably 50% or higher. In an embodiment, the porosity ranges between about 75% and about 99%. In any of the embodiments described herein, it is to be understood that the particle shapes may be regular or irregular, including but not limited to spherical, rod-like, other shapes, etc.
- agent(s) e.g., protein
- MNS/MNP a multi-nuclear polypeptide
- distinct multiple release of three model proteins from the scaffold has been achieved through the control over particle/sphere degradation rates. It is believed that the particle/sphere-scaffold system could serve as a multiple agent delivery carrier as well as a conductive matrix for tissue engineering applications.
- Poly(lactide-co-glycolide) (PLGA) microspheres were fabricated by a double emulsion technique. About 100 ⁇ l of an aqueous model protein solution (fluorescein isothiocyanate bovine serum albumin, FITC-BSA, tetramethylrhodamine isothiocyanate bovine serum albumin, TRITC-BSA, Alexa Fluor ® 350 labeled bovine serum albumin, AF350-BSA, or TRITC-B S A/FITC-dextr an) was emulsified into ImI of 10%
- PLGA/dichloromethane (DCM) solution using a probe sonicator at 15W (Virsonic 100, Gardiner, NY) for 10 seconds over an ice bath to form the primary water-in-oil (w/o) emulsion.
- the w/o emulsion was mixed with 20 ml 1% PVA aqueous solution under sonication to form a water-in-oil-in-water (w/o/w) double emulsion.
- the solution was then stirred magnetically at room temperature for at least 3 hours to evaporate dichloromethane, and subsequently centrifuged to collect solid microspheres.
- the resultant microspheres were washed with distilled water twice, freeze dried and stored under vacuum.
- the microspheres have spherical shapes ( Figure IA). The average size of the microspheres was 557 nm, 260 nm and 345 nm for PLGA50-6.5K, PLGA50-64K and PLGA75-113K, respectively, as determined by dynamic light scattering (L&N Microtrac Particle Analyzer 9200).
- the size of the microspheres was mainly controlled by the strength of sonication during emulsification.
- Figure IB shows the size distribution of PLGA50-64K microspheres.
- the loading efficiency was between about 75% and about 87% for BSA containing microspheres and about 47% for dextran containing microspheres, respectively.
- Example 2 Preparation ofmacroporous scaffold with nano-fibrous structure
- Three-dimensional macroporous nano-fibrous poly(L-lactide) (PLLA) scaffolds were prepared using sugar sphere template leaching and phase separation techniques as follows.
- sugar spheres with different sizes were prepared by an emulsion technique. Specifically, 50 grams of D-fructose (Sigma) was melted at 120 0 C for 90 minutes until clear yellowish liquid was obtained. The liquefied sugar was emulsified into 50 ml mineral oil with 1.3 ml Span80 at 120 0 C under stirring. The resulting mixture was cooled down using an ice-bath to solidify sugar spheres.
- D-fructose Sigma
- the liquefied sugar was emulsified into 50 ml mineral oil with 1.3 ml Span80 at 120 0 C under stirring.
- the resulting mixture was cooled down using an ice-bath to solidify sugar spheres.
- the sugar spheres were washed with hexane three times and sieved to select desired size (180-250, 250-425, 425-600 ⁇ m size ranges).
- the sieved sugar spheres were packaged in a Teflon vial with hexane and treated at 37°C for a certain time to form a sugar template. After bonding the sugar spheres together, hexane was removed, and the sugar template was dried under vacuum.
- the scaffold has characteristics of high porosity (i.e., about 97.5%) well interconnected macroporous structures (e.g., macropores of about 250 ⁇ m - 425 ⁇ m using about 250 ⁇ m - 425 ⁇ m sugar spheres and inter-pore openings of about 80 ⁇ m -120 ⁇ m), and nano-f ⁇ brous pore wall structure (Figure 2). It is believed that these features of the scaffold allow effective cell seeding and facilitate nutrient and waste transport during cell culture. It is to be understood that the porosity percentage and interconnect sizes of this example scaffold are meant to be illustrative and non-limiting. It is to be further understood that different porosity percentages and interconnect sizes may be more suitable for other applications (e.g., tissue engineering applications). Furthermore, the phrase "high porosity" as used herein means porosity ranging from about 50% to about 99%.
- Example 3 Preparation of macroporous scaffold with microporous or solid structure
- the procedures used for fabrication of nano-fibrous scaffolds were applied to prepare macroporous scaffold with microporous or "solid" pore walls by choosing different solvent systems. Instead of THF, dioxane and dichloromethane were used to create microporous structure ( Figures 3 A & 3B) and solid pore wall structure ( Figures 3 C & 3D), respectively.
- the method used for solid scaffold fabrication are not restricted to poly(L- lactic acid) (PLLA) scaffolds.
- biodegradable polymers including, but not limited to poly(lactic-co-glycolic acid) (PLGA), poly(D,L-lactic acid) (PDLLA), polycaprolactone (PCL), polycarbonates, blends of these polymers, and combinations thereof can be used to fabricate scaffolds.
- PLGA poly(lactic-co-glycolic acid)
- PLLA poly(D,L-lactic acid)
- PCL polycaprolactone
- polycarbonates blends of these polymers, and combinations thereof
- Various synthetic non-degradable polymers, or natural macromolecules can also be fabricated into porous materials using this process.
- Example 4 Incorporation of PLGA microspheres into PLLA nano-fibrous scaffold (post-seeding)
- microspheres MS were suspended in substantially pure hexane or an ethanol/water mixture solvent with a concentration of 5 mg MS/ml.
- About 80 ⁇ l of the suspension was seeded onto each PLLA nano-f ⁇ brous scaffold (7.2 mm in diameter by 2 mm in thickness, prepared in Example 3), and the scaffold was left in air for about 30 minutes to evaporate solvent. After that, another 80 ⁇ l of suspension was dropped onto the other side of the scaffold.
- the whole procedure was repeated twice, resulting in about 1.6 mg of microspheres in each scaffold.
- the scaffold can be subjected to a mixture solvent of hexane/THF (volume ratio of 90/10) to adhere the microspheres to nano fibers in the scaffold, and was vacuum-dried for 3 days to remove the solvent. It is to be understood that two or more types of microspheres can be post-seeded into the scaffold simultaneously.
- the distribution of microspheres in scaffold was examined using SEM and laser scanning confocal microscopy (LSCM, Bio-Rad MRC-600, exciting wavelength 488 nm and 568 nm for FITC and TRITC labeled proteins, respectively).
- microspheres did not substantially interfere with the macro and microstructures of the nano- fibrous scaffolds ( Figures 4 A & 4B).
- the microspheres were distributed substantially uniformly on the entire pore wall surfaces throughout the nano-fibrous scaffold and adhered to the nano fibers ( Figures 4A-4E).
- Figures 4B and 4C show the scanning electron micrographs of nano-fibrous scaffold in which about 1.6 mg and 0.16 mg microspheres were incorporated, respectively, into the scaffold.
- the concentration of microsphere suspension used was 2 mg MS/ml, and one single seeding (80 ⁇ l suspension) was employed, as compared to 5 mg MS/ml and four seedings for Figure 4B.
- Example 6 Incorporation of PLGA microspheres into PLLA solid scaffolds prepared by traditional solvent casting/salt-leaching method— post-seeding
- the scaffold has irregular closed pore structures.
- the distribution of microspheres in the scaffold was not as uniform as those in the macroporous interconnected scaffold formed using an embodiment of the method disclosed herein (Example 4).
- Example 7 Effects of solvent/non-solvent post-treatment on the microsphere morphology within the scaffold
- the post-treatment after seeding is generally an important factor for physically adhering microspheres to scaffold structures.
- a polymer solvent/non-solvent mixture (hexane/THF, ethanol/acetone, isopropanol/acetone) was chosen to treat the post-seeded microsphere- scaffold composites.
- About 80 ⁇ l solvent/non-solvent mixture was added to each microsphere-scaffold, which was then vacuum-dried.
- Figure 6 shows the morphology of microspheres in scaffold after different solvent treatments.
- the post-seeding method can also be applied to incorporate PLGA microspheres into naturally derived polymers, such as chitosan, gelatin, and/or alginate scaffolds.
- Chitosan 85% deacetylated, Sigma
- the solution was freeze- dried to obtain a porous chitosan scaffold, which was then cross-linked in a 5% aqueous sodium citrate solution for 5 minutes and freeze-dried again.
- PLGA microspheres were suspended in cyclohexane and seeded onto the sugar template. After evaporation of solvent, polymer casting and phase separation were performed following the same procedures used for scaffold fabrication (Example 3). The microspheres were entrapped in the nano-f ⁇ brous networks throughout the scaffold ( Figure 7). The maintained macroporous structure will advantageously allow the diffusion of proteins released from incorporated microspheres in the scaffold.
- Hydrophilic chitosan/gelatin microspheres were prepared using an in situ emulsion cross-linking technique. Chitosan (85% deacetylated, Sigma) and gelatin (Type B from bovine skin, Sigma) were dissolved in 2% acetic acid at 37°C to obtain a homogeneous solution with concentrations of 2.5 w/v% and 5 w/v% for chitosan and gelatin, respectively. FITC-BSA was added to the homogeneous solution in a concentration of 2.5 mg/ml.
- FITC-BS A/chitosan/gelatin solution was dropped slowly under sonication (15W) to 50 ml of soybean oil with 2 ml Span80 (pre-heated at 47 °C).
- the resulting emulsion was mechanically stirred at 37 °C for about 20 minutes, and was then rapidly cooled down in an ice bath for another 20 minutes to solidify the chitosan/gelatin microspheres.
- about 10 ml of sodium citrate (5% aqueous solution) was added to cross-link the chitosan for about 20 minutes.
- the cross-linked microspheres were separated from oil by centrifugation and washed with 5% sodium citrate once, distilled water twice, 2-propanol twice, and acetone twice, and finally were vacuum dried.
- the hydrophilic chitosan/gelatin (CG) microspheres were characterized using SEM and light scattering to have an average diameter of about 3.51 ⁇ m ( Figures 8A and 8B). A loading efficiency of 63% was achieved.
- the degree of cross-linking may be controlled by varying the concentration of cross-linker (e.g. sodium citrate) and cross-linking time. Without being bound to any theory, it is believed that higher concentration and longer cross- linking time lead to higher degree of cross-linking, which thereby decreases the release rate.
- Example 11 Incorporation ofhydrophilic microspheres into macroporous scaffold
- CG microspheres were suspended in PLLA/THF solution and then cast into the sugar template followed by the same procedure for nano-fibrous scaffold fabrication (Example 3). Resulting scaffolds are shown in Figure 9.
- Example 12 Incorporation ofhydrophilic microspheres into scaffolds prepared by phase separation Hydrophilic chitosan/gelatin (CG) microspheres with diameters ranging from about
- PLGA50-6.5K microspheres degraded very fast with 80% of mass loss within 3 weeks while the mass of PLGA75-113K microspheres was not reduced significantly in 8 weeks.
- PLGA50-64K microspheres were quickly degraded after a 2-week degradation delay. The results indicate that the degradation rate of the microspheres may be modulated by varying the molecular weight and the ratio of lactide/glycolide of PLGA copolymer.
- the degradation of microspheres after incorporation into the scaffold (post-seeding) was also monitored by SEM for morphology changes (Figure 12). Spherical microspheres attached to the nanofibers were initially separate.
- the microspheres changed to a deformed irregular morphology, then merged together with nano fibers, and finally disappeared to expose the original nano fibers.
- the total degradation times of PLGA50-6.5K and PLGA50-64K are 3 weeks and 5 weeks, respectively. However, most PLGA75-113K microspheres remained unchanged in the scaffold after 8 weeks.
- Example 14 Protein release kinetics from microspheres In vitro release of microspheres alone was carried out in PBS according to the same procedure for degradation.
- BSA was released from the PLGA50-6.5K microspheres very fast, more than 90% of BSA was released within 7 days.
- PLGA50-64K microspheres exhibited a multi-phasic release pattern, starting from initial burst release of 40% in 1 day, followed by a slow and sustained release of 20% between day 3 and day 35, then a second burst release of 20% between day 35 to day 42 followed by another sustained release of the remaining BSA. It is believed that the second burst release resulted from degradation of the polymer.
- PLGA75-113K microspheres exhibited a sustained slow release in 0.4% per day for 60 days after an initial burst release of 28%.
- Example 15 Design ofmicrosphere-incorporated nano-fibrous scaffold for multiple protein release
- a macroporous nano-fibrous scaffold has been chosen for the incorporation of three protein-loaded microspheres (TRITC/PLGA50-6.5K, FITC/PLGA50-64K and AF350/PLGA75-113K) ( Figures 14A- 14D).
- the three-dimensional interconnected porous structure of the scaffold was well maintained.
- In vitro release study of microsphere incorporated scaffold (MS-scaffold) was carried out in ImI PBS with 5mM SDS (sodium dodecyl sulfate) at 37 0 C under orbital shaking.
- Samples of release medium were taken at various time points and analyzed on a fluorometer (Fluoromax-2) for fluorescent BSA detection.
- the exciting/emission wavelengths are 495/515 nm for FITC, 544/570 nm for TRITC, and 346/442nm for AF350, respectively.
- Figure 15A shows individualized release profiles of the two proteins, i.e., TRITC- BSA (in PLGA50-6.5K MS) and FITC-BSA (in PLGA50-64K MS) from a PLLA scaffold.
- the release pattern from the MS-scaffold consists of a fast release of TRITC-BSA and a multi-phasic release of FITC-BSA, which was similar to that from the two microspheres alone.
- Example 17 Drug-containing microspheres were also incorporated into the scaffold by a pre-seeding method.
- PLGA50-6.5K (TRITC-BSA) and PLGA75-113K (FITC-BSA) microspheres were incorporated into the PLLA nano-f ⁇ brous scaffold by methods previously described herein.
- the dual release profile from the scaffold consisted of a fast sustained release (1.2% per day for 40 days) for TRITC-BSA and a slow sustained release (0.16% per day for 50 days) for FITC-BSA (Figure 15C).
- Example 18 PLGA50-6.5K (TRITC-BSA) microspheres and hydrophilic chitosan/gelatin (FITC-BSA) microspheres were incorporated into the scaffold to achieve a dual fast release profile.
- tissue regeneration/engineering can be used for various tissue regeneration/engineering applications. These applications include in vitro methods, in vivo implantation, or their combination.
- cells are essential.
- the cells can be stem cells, such as embryonic stem cells or adult (tissue derived) stem cells, e.g., marrow derived stem cells (MSC).
- the cells may also be differentiated cells (chondrocytes, osteoblast, hepatocyte, fibroblasts, muscle cells, cardiac cells, endothelial cells, epithelial cells, adipose cells, neurons, pancreatic islet cells, or the like, or combinations thereof).
- cells are optional.
- cells may be recruited from the host tissues by the particle-containing porous materials.
- cells may be incorporated in these porous materials to regenerate/repair tissues.
- hepatocytes and sinusoidal endothelial cells can be co-cultured on such a particle-containing porous material.
- the cells may alternatively be stem cells or partially from stem cells.
- the constructs can be cultured in vitro or implanted in vivo.
- various factors such as HGF, VEGF, bFGF, PDGF, or the like, may be incorporated to release over time, thereby enhancing hepatic tissue growth and vascularization.
- cells may be incorporated into the particle-containing porous materials.
- BMPs such as BMP- 2,4,6,7
- Dex ascorbic acid
- bFGF vascular endothelial growth factor
- VEGF vascular endothelial growth factor
- PDGF vascular endothelial growth factor
- Still another example includes the regeneration of cartilage.
- Chondrocytes, MSC and/or ES cells are seeded into the particle-containing porous materials.
- TGF- ⁇ and/or other agents may be released from the particles to enhance cartilage formation.
- Periodontal tissues may also be repaired using the particle-containing porous materials.
- BMPs, PDGF, bFGF, and/or VEGF may be released from the particles to achieved cell recruiting from the host, proliferation in the scaffolds, differentiation into cells to regenerate cementum, periodontal ligament, bone and the vasculature all together.
- Blood vessels, heart valves, skin, tendons, ligaments, muscles, nerves, tooth tissues, and so forth can also be regenerated with the right cells and biological agents/factors in such complex scaffolds with controlled release capacity.
- particle-containing complex porous materials can be used for controlled release purposes, even if tissue regeneration is not the aim.
- the immobilized particles in an interconnected matrix allow more controlled release of the agents of interest because free- moving particles often form aggregates, which have different release profiles from that of an isolated particle.
- both hydrophobic PLGA microspheres and hydrophilic chitosan/gelatin microspheres were incorporated into biodegradable PLLA scaffolds.
- the macro-, micro- and nano- features after microsphere incorporation were well retained, and the microspheres were distributed substantially uniformly throughout the scaffolds.
- the characteristics of the scaffold system will allow the factor/agent release from the microspheres (and/or nanospheres) and facilitate cell penetration and nutrient transport in subsequent tissue regeneration application.
- Embodiments of the materials disclosed herein are advantageously capable of releasing multiple factors from scaffolds. Furthermore, the release kinetics may be regulated by the microspheres.
- the scaffold structure reduces the burst effects of the release. It is believed that this feature allows the modulation of multiple release profiles by selecting the materials for microsphere fabrication. For example, the release kinetics of PLGA microspheres may be tailored by the molecular weight and LA/GA ratio while that of chitosan/gelatin may be modulated by cross-linking strength (concentration and time for cross-linking). Still further, the bioactivity of encapsulated molecules (i.e., agents) maybe preserved in the microspheres until release. The methods and materials disclosed herein allow the delivery of multiple molecules with individualized release profiles to be readily expanded to the delivery of multiple biologically active factors/agents, including hormones, growth factors and DNA for tissue engineering applications.
- a novel micro- or nano-sphere/particle- incorporated nano-fibrous scaffold system is capable of delivering multiple molecules with controlled and individualized profiles.
- the release characteristics may be tailored by varying the properties of microspheres (polymer composition, molecular weight, loading etc.) and the incorporation method.
Abstract
Porous materials and methods for forming them are disclosed. One method for immobilizing micro-particles and/or nano-particles onto internal pore surfaces and/or external pore surfaces of porous materials includes suspending the micro-particles and/or nano-particles in a liquid adapted to swell, soften, and/or deform either the porous materials and/or the particles, thereby forming a liquid-particle suspension. The method further includes adding the suspension to the porous materials; and removing the liquid, thereby forming the porous materials having the micro-particles and/or nano-particles immobilized on the internal pore surfaces and/or the external pore surfaces.
Description
PARTICLE-CONTAINING COMPLEX POROUS MATERIALS
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Patent application Serial No. 60/675,247 filed on April 27, 2005.
STATEMENTREGARDINGFEDERALLY SPONSORED RESEARCH ORDEVELOPMENT
This invention was made in the course of research supported by a grant from the National Institutes of Health (NIH) and the National Institute of Dental and Craniofacial Research (NIDCR), Grant Nos. DEO15384 and DEO14755. The U.S. government has certain rights in the invention.
BACKGROUND
The present disclosure relates generally to controlled release therapeutic materials, and more particularly to such materials formed from particle-containing complex porous materials.
Controlled release of biologically active agents using polymeric materials is a powerful means for a wide variety of therapeutics. Such approaches may be especially advantageous for delivery of therapeutic agents to a localized area to substantially circumvent unwanted systemic side effects, to achieve high local dosages without the use of large quantities of therapeutic agents, and/or to prevent unnecessary destruction or denaturing of the agents in the delivery routes (such as in circulation or the gastrointestinal track).
Though different from drug delivery, tissue engineering/regenerative medicine is another interdisciplinary and multidisciplinary field, which aims to generate biological replacements for damaged tissues, failing organs, and dysfunctional body parts. Still young and growing, the field significantly challenges the current treatment modalities represented
by transplantation, surgical reconstruction, and the usage of prostheses, each of which has inherent limitations. In tissue engineering/regenerative medicine, an artificial temporary extracellular matrix (a.k.a. scaffold) plays an important role as a 3D guidance for cell adhesion, proliferation, and new tissue organization. These scaffold materials are compatible with cells and biological host environments. Such scaffolds also possess the appropriate porous structure suitable for cell penetration, nutrient supplies, and metabolic waste removal. Desirably, they may also encourage needed cell-cell and cell-matrix interactions; and may be biodegradable to eventually fade away after fulfilling the purpose as templates (as this may obviate long-term foreign body reactions and associated complications).
In addition to cells and scaffolds, biological signaling may also be necessary for cell function and tissue regeneration. Endogenous signaling molecules are often not sufficient in quantities or types for regeneration purposes, where the addition of signaling molecules is desirable. For example, when stem cells are used for regeneration, the lineage control often relies on the use of differentiation factors. For in vitro cultures, addition of biological molecules in a culture medium either in a continuous or discrete fashion is often possible. In an in vivo situation, such addition of factors to a cell-scaffold construct or regenerating tissue may be very challenging, if not virtually impossible. Due to the sensitivity of cells to the concentration of biological molecules and because of the short half-lives of many of these agents, controlled release technologies are being introduced into the field of tissue engineering and regenerative medicine.
Many controlled release techniques may potentially be introduced into tissue engineering scaffolds. Those that are relatively easy to adapt have been recently utilized for tissue engineering applications. For example, hydrogels have been used as both drug delivery matrices and tissue engineering scaffolds. Further, growth factors, along with cells, have been incorporated into hydrogel scaffolds to enhance regeneration.
Similarly, biological agents have also been directly added into a polymer or a blend of polymers, and the mixture is then used to fabricate a scaffold. For example, ascorbate-2- phosphate and dexamethasone (AsAP and Dex, agents to enhance osteoblastic differentiation of cells) have been mixed in chloroform, which was used to dissolve poly(d,l-
lactide-co-glycolide) (PLGA). This resulted in a mixture (Dex and AsAP suspended in a PLGA solution). This polymer suspension was mixed with salt particles to fabricate a scaffold using the salt-leaching technique, i.e., after the evaporation of solvent, the salt particles were leached away by water to form pores. Others used a PLLA-PDGF (platelet derived growth factor) emulsion to fabricate foams via freeze-drying, polymers mixed with plasmid DNA to fabricate meshes via electrospinning, or a PLGA-bFGF (basic fibroblast growth factor) emulsion to fabricate porous materials using supercritical CO2 foaming.
There also have been attempts to modify a scaffold with biologically active agents using certain coating techniques. For example, collagen matrix was partially dipped in growth factor solutions, such as bFGF, HGF (hepatocyte growth factor), PDGF-BB, VEGF (vascular endothelial growth factor), or IGF-I (insulin like growth factor- 1), to coat these factors on the matrix. Porous bioglass materials have been coated with a laminin solution to allow for subsequent slow release. An emulsion of a polymer solution and vitamin B12 solution has been used to coat certain porous polymer materials. Basic fibroblast growth factor (bFGF) was complexed with sucralfate and polyHEMA and then coated on PLLA scaffolds to enhance liver tissue formation.
The above-described methods of bioactive agent incorporation may, in some instances, achieve certain slow release purposes, but the control over release profile of a bioactive agent is generally limited. Further, these methods are not suitable for releasing multiple agents with individualized controlled release profiles.
Attempts have been made to use micro- and/or nano-spheres or particles (also referred to herein as "MNS" and/or "MNP", these abbreviations meaning herein, micro- spheresAparticles, nano-spheres/-particles, or combinations thereof) made of polymers (often biodegradable polymers) for incorporating drugs and proteins for controlled release. Attempts are also being made to incorporate the controlled release capacity into scaffolding materials to provide desired bioactive agents. However, the successful realization of such ideas to date has proven technically challenging.
One way of combining factor-containing MNS/MNP with scaffolding materials is to directly load MNS/MNP into a scaffold. For example, MNS/MNP containing transforming growth factors (TGF-βi) have been added into a scaffold to aid chondrogenesis. Gelatin
MNS/MNP containing bFGF have been mixed with preadipocytes and dripped on collagen sponge sheets to engineer adipose tissue. However, this method is limited because the added MNS/MSP may migrate under gravity, physical motion, mechanical interference (stirring, shaking, mechanical stress and so forth), and/or fluid flow. Such migrations may deleteriously lead to undesired distribution or loss of MNS/MNP.
PLGA MNS/MNP encapsulating IGF-I (insulin-like growth factor) and TGF-P1 have been entrapped together with condrocytes in a photopolymerized PEO (polyethylene oxide) hydrogel for cartilage formation. Advantages of such in situ gelling systems include the ability to fill irregularly shaped tissue defects, allowing minimally invasive procedures (such as injection and arthroscopic surgery), and the ease of cell and MNS/MNP incorporation. However, the disadvantages include the non-degradability of PEO, the lack of control over macro- and micro-pore shape and size in the gels, and poor mechanical properties.
Similarly, bFGF-containing PLGA MNS/MNP have been incorporated into alginate gel and crosslinked. The alginate gel was then lyophilized to form solid porous materials as a membrane to release bFGF for enhanced angiogenesis and wound healing. The advantage of this method is that the solid-state form may be more mechanically stable than gels. The disadvantages include the lack of matrix degradability (alginate), the inability of controlling pore shape, and the limited ability of varying pore size. Although different from hydrogels, calcium-phosphate cement was also loaded with PLGA MNS/MNP to release rhBMP-2 (recombinant human bone morphogenetic protein-2). Unfortunately, this system generally has similar disadvantages such as the lack of degradability, and the inability of controlling pore shape and pore size.
Another method of entrapping PLGA MNS/MNP into a porous scaffold is gas foaming. In gas foaming, carbon dioxide (CO2) is usually used as a foaming agent. Solid polymer disks are exposed to high pressure CO2 to allow saturation of CO2 in the polymer. Thermodynamic instability is then created by rapidly releasing CO2 gas from the polymer system, followed by the nucleation and growth of gas bubbles in the material. This method allows protein or DNA powders or PLGA MNS/MNP to be entrapped in the materials. However, the disadvantages of this method include the lack of control over pore size and shape, and a nonporous surface, closed-pore structure, with only between about 10% and
about 30% of interconnected pores. The porosity and interpore connectivity may, in some instances, be improved by combining salt-leaching techniques with the gas foaming process, although eliminating closed pores has yet to be successfully achieved. Additionally, the leaching process may remove a large portion of the incorporated agents in an uncontrolled manner, which is also not desirable. Furthermore, the embedded MNS/MNP in the walls of the porous materials generally lose the desired release profiles of the MNS/MNP.
To make it feasible to suspend PLGA micro-/nano-spheres or particles in a PLGA solution, PLGA MNS/MNP have been coated with a layer of PVA (polyvinyl alcohol). The PLGA solution with suspended PVA-coated MNS/MNP was used with salt particles to fabricate scaffolds based on salt-leaching techniques. Theoretically, the PVA coating does not dissolve in organic solvents such as THF (tetrahydrofuran), thereby potentially preventing the dissolution of PLGA MNS/MNP in a PLGA solution. However, a defect-free PVA layer on a MNS/MNP in suspension has yet to be easily, reproducibly and successfully achieved. Additionally, the embedded MNS/MNP inside the pore walls may not result in controlled release profiles.
As such, it would be desirable to provide controlled release therapeutic materials having desirable control over release profiles of bioactive agent(s). Further, it would be desirable to provide such materials suitable for releasing multiple agents. Still further, it would be desirable to provide such materials with individualized controlled release profiles.
SUMMARY
Porous materials and methods for forming the same are disclosed. One of several methods disclosed herein for immobilizing at least one of micro-particles and nano-particles onto internal pore surfaces and/or external pore surfaces of porous materials includes suspending the micro-particles and/or nano-particles in a liquid adapted to swell, soften, and/or deform either the porous materials and/or the particles, thereby forming a liquid- particle suspension. The method further includes adding the suspension to the porous materials; and removing the liquid, thereby forming the porous materials having the micro- particles and/or nano-particles immobilized on the internal pore surfaces and/or the external pore surfaces.
BRIEF DESCRIPTION OF THE DRAWINGS
Objects, features and advantages of embodiments of the present disclosure will become apparent by reference to the following detailed description and drawings, in which:
Fig. IA is a scanning electron micrograph (SEM) of PLGA50-64K microspheres; Fig. IB is a graph depicting size distribution of PLGA50-64K microspheres, DaVg- =
260nm;
Fig. 2A is a SEM of a PLLA nano-fibrous scaffold at low magnification of 10OX, showing well-interconnected macropores and inter-pore openings;
Fig. 2B is a SEM of a PLLA nano-fibrous scaffold at high magnification of 10,00OX, showing nano-fibrous pore wall surfaces;
Figs. 3 A and 3B are each SEMs of PLLA microporous/solid scaffolds, showing a PLLA macroporous scaffold with microporous pore wall structures;
Figs. 3 C and 3D are each SEMs of PLLA microporous/solid scaffolds, showing a PLLA macroporous scaffold with solid pore wall structures; Figs. 4A and 4B are each SEMs of PLLA nano-fibrous scaffolds post seeded with
PLGA microspheres, showing well maintained macroporous and nano-fibrous scaffolds incorporated with about 1.6 mg PLGA50-64K MS;
Fig. 4C is a SEM of PLLA nano-fibrous scaffolds post seeded with PLGA microspheres, showing well maintained macroporous and nano-fibrous scaffolds incorporated with about 0.16 mg PLGA50-64K MS;
Fig. 4D is a Laser scanning confocal micrograph at 200X of a microsphere- incorporated nano-fibrous PLLA scaffold, post-seeded with TRITC-BSA/PLGA50-6.5K (red) and FITC-BSA/PLGA50-64K (green) microspheres;
Fig. 4E is a Laser scanning confocal micrograph at 200X of a microsphere- incorporated nano-fibrous PLLA scaffold post-seeded with PLGA50-64K microspheres encapsulating TRITC-BSA (red) and FITC-dextran (green);
Figs. 5A and 5B are each SEMs of PLLA microporous/solid scaffolds post-seeded with PLGA microspheres;
Figs. 5C and 5D are each SEMs of microsphere-incorporated solid-walled PLLA scaffold;
Fig. 5E is a SEM of microsphere-incorporated in a solid- walled PLGA85 scaffold;
Fig. 6A is a SEM of a PLGA50-64K microsphere-incorporated PLLA nano-fibrous scaffold without solvent/non-solvent treatment;
Fig. 6B is a SEM of a PLGA50-64K microsphere-incorporated PLLA nano-fibrous scaffold treated with 80 μl hexane/THF (90/10, v/v);
Fig. 6C is a SEM of a PLGA50-64K microsphere-incorporated PLLA nano-fibrous scaffold treated with ethanol/acetone (90/10, v/v);
Fig. 7A is a Laser scanning confocal micrograph at 200X of PLLA nano-fibrous scaffolds pre-seeded with TRITC-BSA/PLGA50-6.5K (red) and FITC-BSA/PLGA50-64K (green) microspheres;
Fig. 7B is a SEM of a PLLA nano-fibrous scaffold pre-seeded with PLGA microspheres;
Fig. 8A is a SEM of chitosan/gelatin microspheres;
Fig. 8B is a graph depicting size distribution of the CG (chitosan/gelatin) microspheres, Diγg. = 3.51 μm;
Fig. 9A is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold pre-seeded with FITC-BSA-CG (chitosan/gelatin) (green) microspheres and post-seeded with TRITC-BSA/PLGA50-6.5K (red);
Fig. 9B is a SEM of CG microsphere pre-seeded PLLA nano-fibrous scaffold; Fig. 1OA is a SEM of chitosan/gelatin (CG) microsphere incorporated PLLA scaffold prepared by PLLA/THF phase separation at -20 0C;
Fig. 1OB is a SEM of chitosan/gelatin (CG) microsphere incorporated PLLA scaffold prepared by PLLA/dioxane phase separation at -20 0C;
Fig. 11 is a graph depicting degradation studies of three PLGA microspheres, with the mass loss of different microspheres shown as a function of degradation time (Average ± SD, n=3);
Fig. 12 A is a degradation characterization of PLGA microspheres after post-seeded into PLLA nano-fibrous scaffold using scanning electron microscopy at 10,000X, PLGA50- 6.5K at O, 3, 7, 21 days;
Fig. 12B is a degradation characterization of PLGA microspheres after post-seeded into PLLA nano-fibrous scaffold using scanning electron microscopy at 10,00OX, PLGA50- 64K at 0, 10, 21, 35 days;
Fig. 12C is a degradation characterization of PLGA microspheres after post-seeded into PLLA nano-fibrous scaffold using scanning electron microscopy at 10,000X, PLGA75- 113K at 0, 21, 35, 56 days;
Fig. 13 is a graph depicting release of FITC-BSA from PLGA microspheres in PBS;
Fig. 14A is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold post-seeded with AF350-BSA/PLGA75-113K microspheres (blue); Fig. 14B is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold post-seeded with FITC-BSA/PLGA50-64K microspheres (green);
Fig. 14C is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold post-seeded with TRITC-BSA/PLGA50-6.5K microspheres (red);
Fig. 14D is a Laser scanning confocal micrograph of a PLLA nano-fibrous scaffold post-seeded with a combination of the three types of microspheres from Figs. 14A - 14C;
Fig. 14E is a graph depicting multiple protein release profiles from microsphere- incorporated nano-fibrous scaffold (TRITC/PLGA50-6.5K, FITC/PLGA50-64K and AF350/PLGA75-113K);
Fig. 15A is a graph depicting dual release profiles from microsphere-incorporated nano-fibrous scaffolds post-seeded with TRITC-BSA/PLGA50-6.5K and FITC- BSA/PLGA50-64K microspheres;
Fig. 15B is a graph depicting dual release profiles from microsphere-incorporated nano-fibrous scaffolds post-seeded with PLGA50-64K microspheres of TRITC-BSA and FITC-dextran; Fig. 15C is a graph depicting dual release profiles from microsphere-incorporated nano-fibrous scaffolds pre-seeded with TRITC-BSA/PLGA50-6.5K and FITC- BSA/PLGA75-113K microspheres; and
Fig. 15D is a graph depicting dual release profiles from microsphere-incorporated nano-fibrous scaffolds pre-seeded with FITC-BSA/CG and post-seeded with TRITC- BSA/PLGA50-6.5K microspheres.
DETAILED DESCRIPTION OF THE EMBODIMENTS
The present inventors have unexpectedly and fortuitously discovered compositions incorporating micro-particles/spheres (ranging from about 10" m to about 10"3 m in dimension) or nano-particles/spheres (ranging from about 10" m to about 10" m in dimension) that may contain a single agent or multiple agents (molecules, ions, and/or their complexes) individually or in combination into a variety of porous materials; as well as methods for forming the same. Such complex porous materials allow for the release of various agents in a controlled fashion. The present methods and/or compositions substantially, advantageously overcome various limitations of the technologies described hereinabove.
In the embodiments disclosed herein, the materials of the particles and/or porous foam material(s) may be any natural or synthetic materials; organic materials, inorganic materials, metallic materials, composites thereof, and/or combinations thereof. In an embodiment, the materials are organic materials. They may be natural or synthetic macromolecules. In one embodiment, the materials are at least one of polymers, proteins, carbohydrates, lipids, and combinations thereof.
Some suitable non-degradable polymers include, but are not limited to water insoluble (hydrophobic) polymers/macromolecules that are suitable include polytetrafiuoroethylene (PTFE), polyvinylchloride (PVC), polyethylenes (PE), polypropylenes (PP), polystyrenes, polyacrylonitrile (PAN), polymethylmethacrylate (PMMA), polyvinylacetate (PVAc), polyphenylene oxide, polypropylene oxide (PPO), polyvinylidene fluoride (PVDF), polybutylene, polyamides (PA, Nylons), polyesters, polycarbonates, polyurethanes, polysiloxanes, polyimides, polyetheretherketone (PEEK), polysulfones, polyethersulphone, cellulose, polysaccharides and their derivatives, and mixtures thereof. When in situ polymerization is used instead of polymers/macromolecules, some exemplary suitable hydrophobic unsaturated monomers include the following: acrylates, methacrylates (eg. methyl methacrylate), ethylene, propylene, tetra- fluoroethylene, styrene, vinyl chloride, vinylidene chloride, vinyl acetate, acrylonitrile, 2,2- bis[4-(2-hydroxy-3-methacryloyloxy-propyloxy)-phenyl] propane (Bis-GMA), ethyleneglycol dimethacrylate (EGDMA), tri-ethyleneglycol dimethacrylate (TEGDMA),
bis(2-methacryly-oxyethyl) ester of isophthalic acid (MEI), bis(2-meth-acrylyoxyethyl) ester of terephthalic acid (MET), bis(2-methacrylyoxyethyl) ester of phthalic acid (MEP), 2,2- bis(4-methacrylyoxy phenyl) propane (BisMA), 2,2-bis[4-(2-methacrylyloxyethoxy) phenyl] propane (BisEMA), 2,2-bis[4-(3-methacrylyloxy-propoxy) phenyl] propane (BisPMA), hexafluoro-l,5-pentanediol dimethacrylate (HFPDMA), bis-(2-methacrylyloxyethoxy- hexafluoro-2 -propyl) benzene [Bis(MEHFP)φ], l,6-bis(methacrylyloxy-2- ethoxycarbonylamino)-2,4,4-tri-methylhexan (UEDMA), spiro orthocarbonates, other vinyl monomers, the derivatives of these monomers, and mixtures thereof. Monomers of condensation polymers may also be used to form the porous materials in situ. Some exemplary monomer types in this category are diacids and diols (pairs), ω-hydroxy carboxylic acids, lactones, diacids and diamines (pairs), amino acids, lactams, diisocyanates, diols (pairs), and/or combinations thereof.
Biodegradable polymers and macromolecules may also be used, especially when controlled release properties are desired. Some exemplary, non-limitative biodegradable polymers are given here: poly(lactide-co-glycolide) (PLGA), poly(L-lactic acid) (PLLA), poly(D,L-lactic acid) (PDLLA), polyglycolic acid (PGA), polyanhydrides, poly(ortho ethers), poly(ε-caprolactone) (PCL), poly(hydroxy butyrate) (PHB), poly(propylene fumarate) (PPF), polyphosphoesters (PPE), polyphosphazenes, and/or mixtures thereof. There are also degradable natural macromolecules (typically enzymatically degradable) such as collagen, gelatin and many other proteins, carbohydrates, and/or their derivatives.
Some exemplary, non-limitative water-soluble (hydrophilic) polymers/macromolecules that are suitable materials include polyvinyl alcohol, polyethylene oxide (polyethylene glycol), polymethacrylic acid (PMAA), polyvinyl pyrolidone, polyacrylic acid, poly(lysine), poly(allylamine), poly(ethylenimine), poly(acrylamide), poly(acrylamide-co-arylic acid), poly(acrylamide-co-diallyldimethylammonium chloride), poly(vinyl alcohol), poly(ethylene glycol), polyethylene-block-poly(ethylene glycol), poly(propylene glycol), ρoly(2- hydroxypropyl methacrylate), poly(2-hydroxyethyl methyacrylate), poly(4-hydroxystrene), polyethylene monoalcohol, poly(vinyl alcohol-co-ethylene), poly(styrene-co-allyl alcohol), hydroxyethylcellulose, alginate, pectin, chitin, chitosan, dextran, hyaluronic acid, collagen, gelatin, and/or mixtures thereof.
Certain such polymers/macromolecules can also be synthesized in situ for the porous materials fabrication. Some exemplary suitable acid-containing hydrophilic monomers include the following: monomers containing carboxylic acid: acrylic acid, methacrylic acid, 4-vinylbenzoic acid, crotonic acid, oleic acid, elaidic acid, itaconic acid, maleic acid, fumaric acid, acetylenedicarboxylic acid, tricarbollylic acid, sorbic acid, linoleic acid, linolenic acid, eicosapentenoic acid, other unsaturated carboxylic acids, anhydrides, their derivatives, and mixtures thereof; other organic acids such as sulfonic acid, and/or phosphonic acid replacement of the carboxyl group of the above listed unsaturated carboxylic acids, their derivatives, and mixtures thereof. Some exemplary suitable amine- containing hydrophilic monomers include allylmine, 4-vinylaniline, L-lysine, D-lysine, DL- lysine, acrylamide, their derivatives, and mixtures thereof. Some exemplary suitable hydroxyl-containing hydrophilic monomers include 2-hydroxypropyl methacrylate, 2- hydroxyethyl methyacrylate, 4-hydroxystrene, ethylene glycol, propylene glycol, poly(ethylene glycol) acrylate, poly(ethylene glycol) methacrylate, their derivatives, and/or mixtures thereof.
Many natural macromolecules and synthetic polymers may be both hydrophilic and hydrophobic (amphiphilic). They could also be used for certain foam or particle preparations, such as those containing acid, amine, hydroxyl, and/or other hydrophilic groups in some or all of their structural units. Many of them are copolymers in some way containing both hydrophilic and hydrophobic moieties.
The agents incorporated in the controlled release particles (i.e., the micro-particles and/or nano-particles (MNS/MNP)) can be proteins, hormones, DNA, RNA, nutrients, drugs, other biologically regulating agents, and/or the like. It is to be understood that the agents (molecules, ions, or mixtures thereof) are not limited to applications to stimulate cell adhesion, growth, and tissue regeneration. They may be any drugs, pain suppressors, anti- inflammatory agents, sterilizing agents, contraceptives, pesticides, fertilizers, fragrances, spices and so forth. Furthermore, the agents do not have to be biologically active. They could be functional in other ways, such as, for example, controlling pH, varying colors, imparting fluorescence, maintaining humidity, adjusting conductivities, or as morphological modifications.
Some exemplary, non-limitative biologically active agents include bone morphogenetic proteins (such as BMP-2, BMP-3, BMP-4, BMP-6, BMP-7 and so forth), transforming growth factors (TGFs, such as TGF-α and TGF-β), acid fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF, PDGF-BB and so forth), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), nerve growth factor (NGF), insulin, insulin-like growth factors (IGFs), parathyroid hormone (PTH), parathyroid hormone related protein (PTHrP), DNAs that encode various factors including the above listed, double- stranded RNAs (dsRNAs) that interfere (silence) the genes of various factors including the above listed, various biologically functional peptides (RGD and so forth), vitamins, ascorbate-2-phosphate, dexamethasone, 1-glutamine, and so forth. These agents may be delivered alone or in combination to achieve individualized or synchronized delivery to achieve synergistic or additive effects, as partially demonstrated in some examples presented further in this disclosure. It is to be understood that an already fabricated porous material may be used. In these embodiments, the methods generally include immobilizing the micro-/nano- spheres/particles onto the surfaces of internal and external pores of the pre-fabricated porous material. In this specific technology, the micro-/nano-spheres/particles (with or without agents to be released) are suspended in a non-solvent of both the particles and the porous material. The suspension is then added into the porous material.
After evaporation of the non-solvent, the particles are loosely adhered on the internal and external pore surfaces of the porous material. By "loosely adhered," it is meant that the particles could be washed away using a non-solvent of the particles.
Then, a liquid that swells, deforms, or slightly dissolves either or both of particles and porous material (such as a relatively poor solvent, or a mixture of a solvent and a non- solvent of the particles and/or the porous material) is added into the porous materials with the loosely adhered particles. As used herein, the swelling/deforming/slightly dissolving/softening (mentioned below) is meant to mean changes that do not substantially affect the release profiles of the particles and/or porous materials. Significantly swelling, deforming, and/or dissolving would generally affect the release profiles of the incorporated
agents.) The liquid helps the particles to strongly adhere to the internal and external pore surfaces. After the treatment, the liquid is removed (via freeze-drying, vacuum drying, evaporation, or exchange with a non-solvent for neither the particles nor the porous material). This will result in a porous material with strongly adhered micro-/nano-particles on the pore surfaces. By "strongly adhered" is meant that the particles are not easily washed away using a non-solvent of the particles.
In another embodiment, the porous material is fabricated as the immobilization of the MNS/MNP takes place. It is to be understood that (as mentioned herein), template materials (also called porogens) may be used in the fabrication and immobilization processes. A material can be made into a template, or small geometrical (regular or non-regular) elements can be assembled or aggregated into a 3D template. The template is the negative replica of the porous material to be fabricated. The 3D template can be made using various technologies such as programmed fabrication automatically by a machine (rapid prototyping) or batch by batch manually or semi-manually. As a non-limitative example, the geometrical element(s) (one example of which is a sugar sphere) is/are formed via emulsification, solvent extraction, and freeze- or air-drying. It is to be understood that the template/porogen may be formed of any suitable material, non-limitative examples of which are selected from gelatins, collagen, proteins, polypeptides, carbohydrates, polysaccharides, alginate, chitin, chitosan, pectin, salts, sodium hydroxide, sugars, waxes, naphthalene, natural or synthetic water soluble polymers, natural or synthetic non-water soluble polymers, degradable polymers, non-degradable polymers, partially degradable polymers, or combinations thereof.
Generally, in an embodiment in which the template/porogen material is a sugar sphere template/porogen is formed by first making individual sugar spheres, and then bonding the spheres together. To form individual spheres, a sugar material is melted to form a liquefied sugar material. It is to be understood that any suitable sugar material (e.g., carbohydrates that are aldehyde or ketone derivatives of polyhydric alcohols) maybe used. Some non-limitative examples of suitable sugar materials include sucrose, maltose, dextrose and fructose. It is to be further understood that L-sugars, D-sugars, or combinations thereof may be used. In an embodiment, D-fructose is used. The temperature at which the sugar
material is melted will depend upon the sugar material selected. For example, a D-fructose material melts at about 120 0C, when exposed to the heat for about 90 minutes.
The liquefied sugar is then emulsified with a liquid that does not dissolve the sugar (i.e. a non-solvent to the sugar), one non-limitative example of which is mineral oil. In an embodiment, the emulsion is formed at a temperature of about 1200C. The emulsion is then cooled, for example, in an ice-bath. The cooling results in the solidification of emulsion and the formation of the sugar spheres. Any remaining emulsion mixture (e.g., the non-solvent to the sugar) is discarded, and the sugar spheres may be washed/rinsed in any suitable non- solvent to sugar. Some non-limitative examples of suitable non-solvent to sugar washing liquids include hexane, cyclohexane, and/or the like, and/or combinations thereof. The sugar spheres may then be sieved. Desirable sizes for the individual sugar spheres range from about 20 μm to about 2 mm. In an alternate embodiment, the sizes range from about 50μm to 1 mm; and in a further alternate embodiment, from about 180 μm to about 600 μm. To form a sugar sphere template, the individual sugar spheres may be packaged in a container/mold within a substantially non-hydrous environment and treated at a predetermined temperature for a predetermined time, sufficient for the spheres to bond. Without being bound to any theory, it is believed that better control of the sugar spheres is achieved in a substantially non-hydrous environment wherein the sugar spheres do not substantially absorb water from the environment. It is to be understood that any suitable non-hydrous environment may be used, some examples of which include, but are not limited to hexane, other non-hydrous organic liquids, dried air, a vacuum, inert gas(es) (e.g. nitrogen gas), or combinations thereof. It is to be understood that the predetermined temperature and predetermined time may be any as suitable or desired. In a non-limitative example, the predetermined time ranges from about 2 minutes to about 12 hours; and in an alternate embodiment, ranges from about 5 minutes to about 3 hours. In a further non-limitative example, the predetermined temperature ranges from about room temperature to about 1000C; and in an alternate embodiment, ranges from about 35°C to about 600C. In a further alternate embodiment, the predetermined temperature is about 370C. Once bonded, if the non-hydrous environment is a liquid in which the sugar spheres are contained (e.g. hexane), the liquid non-hydrous environment may be removed and the template dried under vacuum.
It is to be understood that the template/porogen may be formed from a predetermined three-dimensional configuration of the material(s) (non-limitative examples of which are described herein). The predetermined three-dimensional configuration of the template/porogen may have any desirable shape, size, surface morphology, and/or combinations thereof. It is to be understood that the configuration of the template/porogen may depend, at least in part, on the desired geometry and/or configuration of the porous material to be formed.
In an embodiment in which geometrical elements are assembled to form the template/porogen, non-limitative examples of the geometrical element shapes include cubic or other geometrically shaped crystals, spheres (e.g., sugar spheres discussed herein), fibers, discs, regular geometric shapes, irregular geometric shapes, and/or combinations thereof.
A suspension of the micro-/nano-particles (with or without agents to be released) in a liquid (may be a mixture) is added onto such a template to coat the complex 3D surface. The liquid is then removed. Another liquid (such as a polymer solution, suspension, or non-polymer solution or suspension) is cast onto the coated template to form a system.
Any volatile components are removed from the system (such as a solvent, a non- solvent, or a mixture) to form a complex material that includes the template, the micro- /nano- spheres/particles, and the non- volatile components of system. Removal of the volatile component(s) may be accomplished in any suitable fashion, such as by evaporation, freeze-drying, sublimation, extraction, and/or the like, and/or combinations thereof. The template material is then removed via any suitable process (such as, for example, dissolving away in a solvent, melting, degrading, and/or the like, and/or combinations thereof). A complex 3D porous material is produced with the immobilized MNS/MNP on the interior surfaces.
In still other embodiments, MNS/MNP are suspended in liquids that can swell, soften, partially dissolve, and/or deform the particles and/or the porous material, but does not dissolve the MNS/MNP and material(s) used to make the porous (foam) material. The MNS/MNP may be suspended in either the liquid or the solution to form a suspension. The suspension is then cast into a mold or on the template of the porous material. In an
embodiment in which the liquid suspension is used, the liquid may be removed, and the particles are left strongly adhered on the internal and external surfaces of the porous material. In an embodiment in which the solution suspension is used, the solvent of the liquid (such as a polymer solution or suspension) may be removed (e.g., via evaporation, vacuum drying, freeze drying, sublimation, or being extracted with a non-solvent of the material), and the MNS/MNP are left entrapped in or on the walls of the formed porous material. A non-limitative example of the composition formed from either of these embodiments includes immobilized alginate/chitosan microspheres in PLLA nano-fibrous scaffolds with or without macro-pores. It is to be understood that multiple types of micro- and/or nano-particles (containing different agents to be released) are allowed to be entrapped in/on the internal and external pore walls of the porous materials using any single or different combinations of the embodiments disclosed herein. Such complex porous materials will allow the tailoring of individualized release profiles for a variety of different agents. Furthermore, any of the embodiments described herein may be formed so that the walls of the porous materials are nano-fibrous (such as those formed using a phase separation technology described in at least some of the examples). The nano-fibrous matrix may also be formed via other techniques, such as electrospinning. It is believed that the nano-fibrous materials provide better 3D transport, such as, for example, better diffusion conditions for released agents. As such, the nano-fibrous porous materials may allow additional control over the release profiles of the agents contained in the micro-/nano- spheres/particles.
It is to be understood that the pore size of the porous materials described herein may be designed in the nano-size range (10~9 to 10"6m in dimension), micro-size range (10"6 to 10"3 m in dimension), macro-size range (10"3 m or larger in dimension), or multiple size ranges, although some preferred size ranges are the nano-size, micro-size, the lower end of the macro-size (10"3 to 10"2m), and/or combinations thereof.
It is to be further understood that the porosity of the porous materials may be 30% or higher, preferably 50% or higher. In an embodiment, the porosity ranges between about 75% and about 99%.
In any of the embodiments described herein, it is to be understood that the particle shapes may be regular or irregular, including but not limited to spherical, rod-like, other shapes, etc.
To further illustrate embodiment(s) of the present disclosure, various examples are given herein. It is to be understood that these examples are provided for illustrative purposes and are not to be construed as limiting the scope of the disclosed embodiment(s).
In the following examples, the present inventors have developed a unique technique(s) to incorporate agent(s) (e.g., protein) containing MNS/MNP into a nano-fϊbrous scaffold which is highly porous and interconnected. In one example, distinct multiple release of three model proteins from the scaffold has been achieved through the control over particle/sphere degradation rates. It is believed that the particle/sphere-scaffold system could serve as a multiple agent delivery carrier as well as a conductive matrix for tissue engineering applications.
Example 1 Preparation of PLGA microspheres
Poly(lactide-co-glycolide) (PLGA) microspheres were fabricated by a double emulsion technique. About 100 μl of an aqueous model protein solution (fluorescein isothiocyanate bovine serum albumin, FITC-BSA, tetramethylrhodamine isothiocyanate bovine serum albumin, TRITC-BSA, Alexa Fluor® 350 labeled bovine serum albumin, AF350-BSA, or TRITC-B S A/FITC-dextr an) was emulsified into ImI of 10%
PLGA/dichloromethane (DCM) solution, using a probe sonicator at 15W (Virsonic 100, Gardiner, NY) for 10 seconds over an ice bath to form the primary water-in-oil (w/o) emulsion. The w/o emulsion was mixed with 20 ml 1% PVA aqueous solution under sonication to form a water-in-oil-in-water (w/o/w) double emulsion. The solution was then stirred magnetically at room temperature for at least 3 hours to evaporate dichloromethane, and subsequently centrifuged to collect solid microspheres. The resultant microspheres were washed with distilled water twice, freeze dried and stored under vacuum.
Three different PLGA copolymers were used for microsphere fabrication: PLGA50- 6.5K, LA/GA=50/50, Mw=6.5KDa; PLGA50-64K, LA/GA=50/50, Mw=64kDa; PLGA75- 113K, LA/GA=75/25, Mw=I 13IdDa. The microspheres have spherical shapes (Figure IA).
The average size of the microspheres was 557 nm, 260 nm and 345 nm for PLGA50-6.5K, PLGA50-64K and PLGA75-113K, respectively, as determined by dynamic light scattering (L&N Microtrac Particle Analyzer 9200). The size of the microspheres was mainly controlled by the strength of sonication during emulsification. Figure IB shows the size distribution of PLGA50-64K microspheres. The loading efficiency was between about 75% and about 87% for BSA containing microspheres and about 47% for dextran containing microspheres, respectively.
Example 2 Preparation ofmacroporous scaffold with nano-fibrous structure Three-dimensional macroporous nano-fibrous poly(L-lactide) (PLLA) scaffolds were prepared using sugar sphere template leaching and phase separation techniques as follows. First, sugar spheres with different sizes were prepared by an emulsion technique. Specifically, 50 grams of D-fructose (Sigma) was melted at 1200C for 90 minutes until clear yellowish liquid was obtained. The liquefied sugar was emulsified into 50 ml mineral oil with 1.3 ml Span80 at 1200C under stirring. The resulting mixture was cooled down using an ice-bath to solidify sugar spheres. After discarding the mineral oil, the sugar spheres were washed with hexane three times and sieved to select desired size (180-250, 250-425, 425-600 μm size ranges). The sieved sugar spheres were packaged in a Teflon vial with hexane and treated at 37°C for a certain time to form a sugar template. After bonding the sugar spheres together, hexane was removed, and the sugar template was dried under vacuum.
About 0.6 ml to about 0.8 ml 10% PLLA/THF solution was cast into the assembled sugar template. Mild vacuum was applied during the casting in order to fully fill the interspaces of the bonded sugar sphere template with polymer solution. The polymer solution in sugar template was phase separated at a temperature ranging from about 2O0C to about -1960C (in an embodiment, the temperature is equal to or less than 160C) overnight and then immersed into cyclohexane to exchange THF for 2 days. The resulting composites were freeze-dried, and the sugar was leached away in distilled water. The samples were freeze-dried again to obtain highly porous nano-fibrous scaffolds.
The scaffold has characteristics of high porosity (i.e., about 97.5%) well interconnected macroporous structures (e.g., macropores of about 250 μm - 425 μm using about 250 μm - 425 μm sugar spheres and inter-pore openings of about 80 μm -120 μm), and nano-fϊbrous pore wall structure (Figure 2). It is believed that these features of the scaffold allow effective cell seeding and facilitate nutrient and waste transport during cell culture. It is to be understood that the porosity percentage and interconnect sizes of this example scaffold are meant to be illustrative and non-limiting. It is to be further understood that different porosity percentages and interconnect sizes may be more suitable for other applications (e.g., tissue engineering applications). Furthermore, the phrase "high porosity" as used herein means porosity ranging from about 50% to about 99%.
Example 3 Preparation of macroporous scaffold with microporous or solid structure The procedures used for fabrication of nano-fibrous scaffolds were applied to prepare macroporous scaffold with microporous or "solid" pore walls by choosing different solvent systems. Instead of THF, dioxane and dichloromethane were used to create microporous structure (Figures 3 A & 3B) and solid pore wall structure (Figures 3 C & 3D), respectively. The method used for solid scaffold fabrication are not restricted to poly(L- lactic acid) (PLLA) scaffolds. Many biodegradable polymers including, but not limited to poly(lactic-co-glycolic acid) (PLGA), poly(D,L-lactic acid) (PDLLA), polycaprolactone (PCL), polycarbonates, blends of these polymers, and combinations thereof can be used to fabricate scaffolds. Various synthetic non-degradable polymers, or natural macromolecules (degradable or non-degradable) can also be fabricated into porous materials using this process.
Example 4 Incorporation of PLGA microspheres into PLLA nano-fibrous scaffold (post-seeding) In post-seeding method(s), drug-containing PLGA50-64K (LA/GA=50/50, Mw=64 IcDa) microspheres (MS) were suspended in substantially pure hexane or an ethanol/water mixture solvent with a concentration of 5 mg MS/ml. About 80 μl of the suspension was seeded onto each PLLA nano-fϊbrous scaffold (7.2 mm in diameter by 2 mm in thickness,
prepared in Example 3), and the scaffold was left in air for about 30 minutes to evaporate solvent. After that, another 80μl of suspension was dropped onto the other side of the scaffold. The whole procedure was repeated twice, resulting in about 1.6 mg of microspheres in each scaffold. The scaffold can be subjected to a mixture solvent of hexane/THF (volume ratio of 90/10) to adhere the microspheres to nano fibers in the scaffold, and was vacuum-dried for 3 days to remove the solvent. It is to be understood that two or more types of microspheres can be post-seeded into the scaffold simultaneously. The distribution of microspheres in scaffold was examined using SEM and laser scanning confocal microscopy (LSCM, Bio-Rad MRC-600, exciting wavelength 488 nm and 568 nm for FITC and TRITC labeled proteins, respectively). The incorporation of microspheres did not substantially interfere with the macro and microstructures of the nano- fibrous scaffolds (Figures 4 A & 4B). The microspheres were distributed substantially uniformly on the entire pore wall surfaces throughout the nano-fibrous scaffold and adhered to the nano fibers (Figures 4A-4E). By adjusting the concentration of microsphere suspension and seeding times, one can easily control the amount of microspheres incorporated into the scaffold, which, in turn, can modulate the dose of protein released from the scaffold. Figures 4B and 4C show the scanning electron micrographs of nano-fibrous scaffold in which about 1.6 mg and 0.16 mg microspheres were incorporated, respectively, into the scaffold. In Figure 4C, the concentration of microsphere suspension used was 2 mg MS/ml, and one single seeding (80 μl suspension) was employed, as compared to 5 mg MS/ml and four seedings for Figure 4B.
Example 5 Incorporation of PLGA microspheres into PLLA and PLGA85 macroporous solid scaffolds— post-seeding PLGA50-6.5K microspheres (LA/GA=50/50, Mw=6.5 kDa) were also post-seeded into PLLA or PLGA85 (LA/GA=85:15) macroporous scaffolds with microporous or solid structures (developed in Example 4). Scanning electron micrographs demonstrated the well- interconnected macroporous structures with PLGA50-6.5K microspheres entrapped in entire internal pore wall surfaces throughout the scaffold (Figure 5).
Example 6 Incorporation of PLGA microspheres into PLLA solid scaffolds prepared by traditional solvent casting/salt-leaching method— post-seeding
PLGA50-6.5K microspheres (LA/GA=50/50, Mw=6.5 kDa) were post-seeded into PLLA solid scaffolds prepared by traditional solvent casting/salt-leaching method. This is an example of an embodiment in which a previously fabricated porous material is used. The scaffold has irregular closed pore structures. The distribution of microspheres in the scaffold was not as uniform as those in the macroporous interconnected scaffold formed using an embodiment of the method disclosed herein (Example 4).
Example 7 Effects of solvent/non-solvent post-treatment on the microsphere morphology within the scaffold
In post-seeding methods for incorporation of microspheres into the scaffold, the post-treatment after seeding is generally an important factor for physically adhering microspheres to scaffold structures. A polymer solvent/non-solvent mixture (hexane/THF, ethanol/acetone, isopropanol/acetone) was chosen to treat the post-seeded microsphere- scaffold composites. About 80 μl solvent/non-solvent mixture was added to each microsphere-scaffold, which was then vacuum-dried. Figure 6 shows the morphology of microspheres in scaffold after different solvent treatments.
Example 8 Incorporation of PLGA microspheres into naturally derived polymer scaffolds — post-seeding
The post-seeding method can also be applied to incorporate PLGA microspheres into naturally derived polymers, such as chitosan, gelatin, and/or alginate scaffolds. Chitosan (85% deacetylated, Sigma) was dissolved in about 2% acetic acid to obtain a substantially homogeneous solution with concentrations of about 2.5 w/v%. The solution was freeze- dried to obtain a porous chitosan scaffold, which was then cross-linked in a 5% aqueous sodium citrate solution for 5 minutes and freeze-dried again. About 80 μl PLGA50-6.5K microsphere suspension in ethanol/water (80/20, v/v) was seeded into the chitosan scaffold (7.2 mm in diameter and 2 mm in thickness). The resulting microsphere-scaffold was vacuum dried.
Example 9 Incorporation of hydrophobic microspheres into scaffold (pre-seeding)
In an alternative pre-seeding method, PLGA microspheres were suspended in cyclohexane and seeded onto the sugar template. After evaporation of solvent, polymer casting and phase separation were performed following the same procedures used for scaffold fabrication (Example 3). The microspheres were entrapped in the nano-fϊbrous networks throughout the scaffold (Figure 7). The maintained macroporous structure will advantageously allow the diffusion of proteins released from incorporated microspheres in the scaffold.
Example 10 Preparation of chitosan/ gelatin microspheres
Hydrophilic chitosan/gelatin microspheres were prepared using an in situ emulsion cross-linking technique. Chitosan (85% deacetylated, Sigma) and gelatin (Type B from bovine skin, Sigma) were dissolved in 2% acetic acid at 37°C to obtain a homogeneous solution with concentrations of 2.5 w/v% and 5 w/v% for chitosan and gelatin, respectively. FITC-BSA was added to the homogeneous solution in a concentration of 2.5 mg/ml. About 2 ml of FITC-BS A/chitosan/gelatin solution was dropped slowly under sonication (15W) to 50 ml of soybean oil with 2 ml Span80 (pre-heated at 47 °C). The resulting emulsion was mechanically stirred at 37 °C for about 20 minutes, and was then rapidly cooled down in an ice bath for another 20 minutes to solidify the chitosan/gelatin microspheres. After that, about 10 ml of sodium citrate (5% aqueous solution) was added to cross-link the chitosan for about 20 minutes. The cross-linked microspheres were separated from oil by centrifugation and washed with 5% sodium citrate once, distilled water twice, 2-propanol twice, and acetone twice, and finally were vacuum dried. The hydrophilic chitosan/gelatin (CG) microspheres were characterized using SEM and light scattering to have an average diameter of about 3.51 μm (Figures 8A and 8B). A loading efficiency of 63% was achieved. The degree of cross-linking may be controlled by varying the concentration of cross-linker (e.g. sodium citrate) and cross-linking time. Without being bound to any theory, it is believed that higher concentration and longer cross- linking time lead to higher degree of cross-linking, which thereby decreases the release rate.
Example 11 Incorporation ofhydrophilic microspheres into macroporous scaffold
To incorporate hydrophilic chitosan/gelatin (CG) microspheres into nano-fibrous scaffold, CG microspheres were suspended in PLLA/THF solution and then cast into the sugar template followed by the same procedure for nano-fibrous scaffold fabrication (Example 3). Resulting scaffolds are shown in Figure 9.
Example 12 Incorporation ofhydrophilic microspheres into scaffolds prepared by phase separation Hydrophilic chitosan/gelatin (CG) microspheres with diameters ranging from about
10 μm to about 30 μm were suspended in PLLA/THF or PLLA/dioxane solution homogenously under stirring. The mixture solution was then subject to phase separation at a temperature ranging from about 40C to about -196 0C overnight. The phase separated sample was then freeze dried to obtain final CG microsphere incorporated nano-fϊbrous (Figure 1 OA) or solid scaffolds (Figure 1 OB).
Example 13 Degradation of PLGA microspheres and microsphere-incorporated scaffold
The degradation of microspheres was conducted in phosphate saline buffer (PBS, 10 mM, pH=7.4). About 10 mg of microspheres (three different microsphere formulations: PLGA50-6.5K, PLGA50-64K, and PLGA75-113 K) were suspended in 1 ml PBS and incubated at 37°C under continuous orbital shaking at 60 rpm. At various time points, the microspheres were collected by centrifugation, washed with distilled water twice, and vacuum-dried. The mass loss was obtained as a function of degradation time. The degradation rate of three microspheres was dramatically different because of different molecular weights and LA/GA ratios of the copolymer (Figure 11). PLGA50-6.5K microspheres degraded very fast with 80% of mass loss within 3 weeks while the mass of PLGA75-113K microspheres was not reduced significantly in 8 weeks. PLGA50-64K microspheres were quickly degraded after a 2-week degradation delay. The results indicate that the degradation rate of the microspheres may be modulated by varying the molecular weight and the ratio of lactide/glycolide of PLGA copolymer.
The degradation of microspheres after incorporation into the scaffold (post-seeding) was also monitored by SEM for morphology changes (Figure 12). Spherical microspheres attached to the nanofibers were initially separate. During degradation, the microspheres changed to a deformed irregular morphology, then merged together with nano fibers, and finally disappeared to expose the original nano fibers. The total degradation times of PLGA50-6.5K and PLGA50-64K are 3 weeks and 5 weeks, respectively. However, most PLGA75-113K microspheres remained unchanged in the scaffold after 8 weeks.
Example 14 Protein release kinetics from microspheres In vitro release of microspheres alone was carried out in PBS according to the same procedure for degradation. The release profiles of a model protein (BSA) from three microsphere formulations (PLGA50-6.5K, PLGA50-64K, PLGA75-113K) followed the degradation kinetics of the polymers, except for the initial burst release and a slight delay for subsequent sustained release (Figure 13). BSA was released from the PLGA50-6.5K microspheres very fast, more than 90% of BSA was released within 7 days. PLGA50-64K microspheres exhibited a multi-phasic release pattern, starting from initial burst release of 40% in 1 day, followed by a slow and sustained release of 20% between day 3 and day 35, then a second burst release of 20% between day 35 to day 42 followed by another sustained release of the remaining BSA. It is believed that the second burst release resulted from degradation of the polymer. PLGA75-113K microspheres exhibited a sustained slow release in 0.4% per day for 60 days after an initial burst release of 28%.
Example 15 Design ofmicrosphere-incorporated nano-fibrous scaffold for multiple protein release To design a multiple protein delivery system, a macroporous nano-fibrous scaffold has been chosen for the incorporation of three protein-loaded microspheres (TRITC/PLGA50-6.5K, FITC/PLGA50-64K and AF350/PLGA75-113K) (Figures 14A- 14D). The three-dimensional interconnected porous structure of the scaffold was well maintained.
In vitro release study of microsphere incorporated scaffold (MS-scaffold) was carried out in ImI PBS with 5mM SDS (sodium dodecyl sulfate) at 37 0C under orbital shaking. Samples of release medium were taken at various time points and analyzed on a fluorometer (Fluoromax-2) for fluorescent BSA detection. The exciting/emission wavelengths are 495/515 nm for FITC, 544/570 nm for TRITC, and 346/442nm for AF350, respectively.
The multiple release of three labeled BSA from one single scaffold was shown in Figure 14E. In a two-week time period, three distinct release profiles were obtained. The initial burst release of all three labeled proteins from scaffold was reduced as compared to that from microsphere alone. After initial release, the scaffold releases TRITC-BSA (from PLGA50-6.5K microspheres) at a fast rate of 3% per day while releases FITC-BSA and AF350-BSA at relative slower rate of 1% and 0.5% per day, respectively from PLGA50- 64K and PLGA75-113K microspheres (incorporated in the scaffold). The results demonstrated that the developed MS-scaffold system was capable of releasing multiple factors with individualized release profiles.
Example 16 Dual protein release kinetics from microspheres-incorporated scaffold
To study the effect of microsphere composition and incorporation method on release kinetics in the long term, a variety of dual release patterns were achieved by incorporating two different microspheres, or by using different incorporation techniques (Figures 15A- 15D). Figure 15A shows individualized release profiles of the two proteins, i.e., TRITC- BSA (in PLGA50-6.5K MS) and FITC-BSA (in PLGA50-64K MS) from a PLLA scaffold. The release pattern from the MS-scaffold consists of a fast release of TRITC-BSA and a multi-phasic release of FITC-BSA, which was similar to that from the two microspheres alone. However, the initial burst release was significantly reduced for both proteins when the microspheres were incorporated into the scaffold. The sustained release of TRITC-BSA (from PLGA50-6.5K) was extended to 28 days while 40% of FITC-BSA (from PLGA50- 64K) was retained in the scaffold, even after 9 weeks. When two different macromolecules (TRITC-BSA and FITC-dextran) were encapsulated into the same PLGA50-64K microspheres (which were subsequently post-seeded on the scaffold), another type of dual
release was obtained. TRITC-BSA and FITC-dextran were released in a similar pattern but in different dosage amounts (Figure 15B). In contrast to TRITC-BSA, FITC-dextran was released faster because of its higher water solubility and smaller molecular chain size.
Example 17. Drug-containing microspheres were also incorporated into the scaffold by a pre-seeding method.
PLGA50-6.5K (TRITC-BSA) and PLGA75-113K (FITC-BSA) microspheres were incorporated into the PLLA nano-fϊbrous scaffold by methods previously described herein. The dual release profile from the scaffold consisted of a fast sustained release (1.2% per day for 40 days) for TRITC-BSA and a slow sustained release (0.16% per day for 50 days) for FITC-BSA (Figure 15C).
Example 18. PLGA50-6.5K (TRITC-BSA) microspheres and hydrophilic chitosan/gelatin (FITC-BSA) microspheres were incorporated into the scaffold to achieve a dual fast release profile.
Because of the fast degradation rate of PLGA-6.5K microspheres and the physical ionic cross-linking characteristic of CG microspheres, both proteins were released fast from the MS-scaffold (Figure 15D).
These particle-containing porous materials can be used for various tissue regeneration/engineering applications. These applications include in vitro methods, in vivo implantation, or their combination. For in vitro tissue regeneration/engineering, cells are essential. The cells can be stem cells, such as embryonic stem cells or adult (tissue derived) stem cells, e.g., marrow derived stem cells (MSC). The cells may also be differentiated cells (chondrocytes, osteoblast, hepatocyte, fibroblasts, muscle cells, cardiac cells, endothelial cells, epithelial cells, adipose cells, neurons, pancreatic islet cells, or the like, or combinations thereof). For in vivo applications, cells are optional. In certain situations, such as a small or a thin layer of defect, cells may be recruited from the host tissues by the particle-containing porous materials. For some other situations, such as large defects or the lack of the needed cells at the implant site, cells may be incorporated in these porous materials to regenerate/repair tissues.
For example, to regenerate liver, hepatocytes and sinusoidal endothelial cells can be co-cultured on such a particle-containing porous material. The cells may alternatively be stem cells or partially from stem cells. The constructs can be cultured in vitro or implanted in vivo. In the particles, various factors such as HGF, VEGF, bFGF, PDGF, or the like, may be incorporated to release over time, thereby enhancing hepatic tissue growth and vascularization.
In another example, to regenerate bone, cells (osteoblasts, MSC, and/or ES cells) may be incorporated into the particle-containing porous materials. BMPs (such as BMP- 2,4,6,7), Dex, ascorbic acid, bFGF, VEGF, and/or PDGF may be incorporated into the particles with individually designed release profiles. These factors will be released in a manner to synergistically stimulate vascularized bone formation.
Still another example includes the regeneration of cartilage. Chondrocytes, MSC and/or ES cells are seeded into the particle-containing porous materials. TGF-β and/or other agents may be released from the particles to enhance cartilage formation. Periodontal tissues may also be repaired using the particle-containing porous materials. BMPs, PDGF, bFGF, and/or VEGF may be released from the particles to achieved cell recruiting from the host, proliferation in the scaffolds, differentiation into cells to regenerate cementum, periodontal ligament, bone and the vasculature all together.
Blood vessels, heart valves, skin, tendons, ligaments, muscles, nerves, tooth tissues, and so forth can also be regenerated with the right cells and biological agents/factors in such complex scaffolds with controlled release capacity.
These particle-containing complex porous materials can be used for controlled release purposes, even if tissue regeneration is not the aim. The immobilized particles in an interconnected matrix allow more controlled release of the agents of interest because free- moving particles often form aggregates, which have different release profiles from that of an isolated particle.
Using microsphere pre- or post-seeding techniques, both hydrophobic PLGA microspheres and hydrophilic chitosan/gelatin microspheres were incorporated into biodegradable PLLA scaffolds. Notably, the macro-, micro- and nano- features after microsphere incorporation were well retained, and the microspheres were distributed
substantially uniformly throughout the scaffolds. Without being bound to any theory, it is believed that the characteristics of the scaffold system will allow the factor/agent release from the microspheres (and/or nanospheres) and facilitate cell penetration and nutrient transport in subsequent tissue regeneration application. Embodiments of the materials disclosed herein are advantageously capable of releasing multiple factors from scaffolds. Furthermore, the release kinetics may be regulated by the microspheres. Another advantageous feature of the materials is that the scaffold structure reduces the burst effects of the release. It is believed that this feature allows the modulation of multiple release profiles by selecting the materials for microsphere fabrication. For example, the release kinetics of PLGA microspheres may be tailored by the molecular weight and LA/GA ratio while that of chitosan/gelatin may be modulated by cross-linking strength (concentration and time for cross-linking). Still further, the bioactivity of encapsulated molecules (i.e., agents) maybe preserved in the microspheres until release. The methods and materials disclosed herein allow the delivery of multiple molecules with individualized release profiles to be readily expanded to the delivery of multiple biologically active factors/agents, including hormones, growth factors and DNA for tissue engineering applications.
In summary, it has been demonstrated that a novel micro- or nano-sphere/particle- incorporated nano-fibrous scaffold system is capable of delivering multiple molecules with controlled and individualized profiles. The release characteristics may be tailored by varying the properties of microspheres (polymer composition, molecular weight, loading etc.) and the incorporation method.
While several embodiments have been described in detail, it will be apparent to those skilled in the art that the disclosed embodiments may be modified. Therefore, the foregoing description is to be considered exemplary rather than limiting.
Claims
1. A method for immobilizing at least one of micro-particles or nano-particles onto at least one of internal pore surfaces or external pore surfaces of porous materials, the method comprising: suspending the at least one of micro-particles or nano-particles in a non-solvent of both the porous materials and the at least one of micro-particles or nano-particles, thereby forming a non-solvent-particle suspension; adding the suspension to the porous materials; removing the non-solvent to form the porous materials having the at least one of micro-particles or nano-particles loosely adhered on at least one of the internal pore surfaces or the external pore surfaces; at least one of swelling, deforming, or slightly dissolving at least one of the porous materials or the at least one of micro-particles or nano-particles by addition of a liquid adapted to perform the at least one of swelling, deforming or slightly dissolving; and removing the liquid, thereby forming the porous materials having the at least one of micro-particles or nano-particles immobilized on the at least one of the internal pore surfaces or the external pore surfaces.
2. The method as defined in claim 1 wherein the at least one of the micro-particles or the nano-particles is selected from natural materials, synthetic materials, organic materials, inorganic materials, metallic materials, composites thereof, and combinations thereof.
3. The method as defined in claim 1 wherein the at least one of the micro-particles or nano-particles is a controlled release particle having an agent embedded therein.
4. The method as defined in claim 3 wherein the agent is selected from proteins, hormones, DNA, RNA, nutrients, drugs, biologically regulating agents, and combinations thereof.
5. The method as defined in claim 3 wherein, prior to suspending the at least one of the micro-particles or nano-particles, the method further comprises varying at least one property of the at least one of the micro-particles or nano-particles, thereby altering at least one release characteristic of the agent.
6. The method as defined in claim 1 wherein removing the liquid is accomplished by at least one of freeze-drying, vacuum drying, evaporation, or exchange with a non-solvent of the particles and the porous material.
7. A method for immobilizing at least one of micro-particles or nano-particles onto at least one of internal pore surfaces or external pore surfaces of porous materials, the method comprising: suspending the at least one of micro-particles or nano-particles in a liquid adapted to at least one of swell, soften, and deform at least one of the porous materials and the at least one of micro-particles or nano-particles, thereby forming a liquid-particle suspension; adding the suspension to the porous materials; and removing the liquid, thereby forming the porous materials having the at least one of the micro-particles or nano-particles immobilized on the at least one of the internal pore surfaces or the external pore surfaces.
8. The method as defined in claim 7 wherein the at least one of the micro-particles or the nano-particles is selected from natural materials, synthetic materials, organic materials, inorganic materials, metallic materials, composites thereof, and combinations thereof.
9. The method as defined in claim 7 wherein the at least one of the micro-particles or nano-particles is a controlled release particle having an agent embedded therein.
10. The method as defined in claim 9 wherein the agent is selected from proteins, hormones, DNA, RNA, nutrients, drugs, biologically regulating agents, and combinations thereof.
11. The method as defined in claim 9 wherein, prior to suspending the at least one of the micro-particles or nano-particles, the method further comprises varying at least one property of the at least one of the micro-particles or nano-particles, thereby altering at least one release characteristic of the agent.
12. The method as defined in claim 7 wherein removing the liquid is accomplished by at least one of freeze-drying, vacuum drying, evaporation, or exchange with a non-solvent of the particles and the porous material.
13. A method for forming a porous material, comprising: coating a suspension or mixture of at least one of micro-particles or nano-particles onto a negative replica of a desired macroporous architecture of the porous material, thereby forming a coated replica, the negative replica having been formed from a predetermined three-dimensional configuration of shaped porogen materials; removing a liquid into which the at least one of the micro-particles or nano-particles was suspended or mixed; casting a second liquid onto the coated replica, thereby forming a system; removing volatile components from the system, thereby forming a complex material including the replica, the at least one of micro-particles and nano-particles, and non- volatile components of the cast, second liquid; and removing the porogen materials from the complex material, thereby forming the porous material having the desired three-dimensional macroporous architecture with the at least one of micro-particles and nano-particles immobilized on interior pore surfaces thereof.
14. The method as defined in claim 13 wherein the second liquid is selected from a polymer solution, a polymer suspension, a non-polymer solution, a non-polymer suspension, and combinations thereof.
15. The method as defined in claim 13 wherein the negative replica is formed of at least one material selected from gelatins, collagen, proteins, polypeptides, carbohydrates, polysaccharides, alginate, chitin, chitosan, pectin, salts, sodium hydroxide, sugars, waxes, naphthalene, natural or synthetic water soluble polymers, natural or synthetic non-water soluble polymers, degradable polymers, non-degradable polymers, partially degradable polymers, and combinations thereof.
16. The method as defined in claim 13 wherein removing the volatile components is accomplished by evaporation, freeze-drying, sublimation, extraction, and combinations thereof.
17. The method as defined in claim 13 wherein removing the porogen materials is accomplished by dissolution in a solvent, melting, degrading, and combinations thereof.
18. The method as defined in claim 13 wherein the at least one of the micro-particles or the nano-particles is selected from natural materials, synthetic materials, organic materials, inorganic materials, metallic materials, composites thereof, and combinations thereof.
19. The method as defined in claim 18 wherein the at least one of the micro-particles or nano-particles is a controlled release particle having an agent embedded therein.
20. The method as defined in claim 19 wherein the agent is selected from proteins, hormones, DNA, RNA, nutrients, drugs, biologically regulating agents, and combinations thereof.
21. A method of making porous foam materials, comprising: suspending at least one of micro-particles and nano-particles in a solution of solvent and materials adapted to form the porous foam materials, the solvent substantially not dissolving the at least one of micro-particles and nano-particles, thereby forming a solution-particles suspension; casting the suspension into a mold or on a template of the porous foam materials; and removing the solvent, thereby forming the porous foam materials having the at least one of micro-particles and nano-particles entrapped in or on walls of the porous foam materials.
22. The method as defined in claim 21 wherein the at least one of the micro-particles or the nano-particles is selected from natural materials, synthetic materials, organic materials, inorganic materials, metallic materials, composites thereof, and combinations thereof.
23. The method as defined in claim 21 wherein the at least one of the micro-particles or nano-particles is a controlled release particle having an agent embedded therein.
24. The method as defined in claim 23 wherein the agent is selected from proteins, hormones, DNA, RNA, nutrients, drugs, biologically regulating agents, and combinations thereof.
25. The method as defined in claim 21 wherein removing the solvent is accomplished by at least one of freeze-drying, vacuum drying, evaporation, or exchange with a non- solvent of the particles and the porous material.
26. A material capable of controllably releasing a biologically active agent, comprising: a porous material having internal pore surfaces and external pore surfaces; and at least one of micro-particles or nano-particles immobilized onto at least one of the internal pore surfaces or the external pore surfaces, the at least one of the micro-particles or nano-particles having a biologically active agent substantially embedded therein.
27. The material as defined in claim 26 wherein the porous material has a porosity of at least 30%.
28. The material as defined in claim 26 wherein the at least one of the micro-particles or the nano-particles is selected from natural materials, synthetic materials, organic materials, inorganic materials, metallic materials, composites thereof, and combinations thereof.
29. The material as defined in claim 26 wherein the biologically active agent is selected from proteins, hormones, DNA, RNA, nutrients, drugs, biologically regulating agents, and combinations thereof.
30. Porous materials formed by the method of claim 1.
31. Porous materials formed by the method of claim 7.
32. Porous materials formed by the method of claim 13.
33. Porous foam materials formed by the method of claim 21.
34. A method for forming a sugar sphere, comprising: melting a sugar material, thereby forming a liquefied sugar material; emulsifying the liquefied sugar material, thereby forming a sugar material emulsion; and solidifying the sugar material emulsion, thereby forming sugar spheres.
35. The method as defined in claim 34 wherein the sugar material is selected from sucrose, maltose, dextrose, fructose, and combinations thereof.
36. The method as defined in claim 34 wherein the sugar material is emulsified in a non-solvent to the sugar material.
37. The method as defined in claim 34, further comprising rinsing the sugar spheres.
38. The method as defined in claim 34 wherein the sugar spheres have a size ranging from about 20 μm to about 2 mm.
39. A method for using the sugar spheres as defined in claim 34, comprising: packaging a plurality of sugar spheres in a mold contained in a substantially non- hydrous environment; and treating the plurality of sugar spheres at a predetermined temperature for a predetermine time sufficient to bond the plurality of sugar spheres together in a predetermined configuration.
40. The method as defined in claim 39 wherein the predetermined temperature ranges from about room temperature to about 1000C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67524705P | 2005-04-27 | 2005-04-27 | |
US60/675,247 | 2005-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006116392A2 true WO2006116392A2 (en) | 2006-11-02 |
WO2006116392A3 WO2006116392A3 (en) | 2007-02-08 |
Family
ID=37215404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/015612 WO2006116392A2 (en) | 2005-04-27 | 2006-04-25 | Particle-containing complex porous materials |
Country Status (2)
Country | Link |
---|---|
US (2) | US8268344B2 (en) |
WO (1) | WO2006116392A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008253558A (en) * | 2007-04-05 | 2008-10-23 | Olympus Corp | Production method of bioprosthesis |
WO2010104593A3 (en) * | 2009-03-13 | 2011-03-03 | President And Fellows Of Harvard College | Systems and methods of templating using particles such as colloidal particles |
CN102327623A (en) * | 2011-09-21 | 2012-01-25 | 黑龙江大学 | Preparation method of DNA (deoxyribonucleic acid) vaccine nanoparticles containing PLGA (Poly-lactide-co-glycolide) for ND (necastle disease) |
CN104414772A (en) * | 2013-09-06 | 2015-03-18 | 山东百多安医疗器械有限公司 | In-vivo degradable and absorbable artificial medical tissue repairing film |
CN104758261A (en) * | 2015-04-30 | 2015-07-08 | 中国医学科学院生物医学工程研究所 | Icariin PLGA nano particles and preparing method and application thereof |
EP3004324A4 (en) * | 2013-06-06 | 2017-01-04 | Sns Nano Fiber Technology, LLC | Three-dimensional structures for cell or tissue culture |
CN108939136A (en) * | 2018-08-20 | 2018-12-07 | 重庆医科大学附属永川医院 | A kind of dressing and preparation method thereof for nose filling hemostasis |
US10272036B2 (en) | 2013-12-06 | 2019-04-30 | Intervet Inc. | Composition for oral delivery of bioactive agents |
Families Citing this family (387)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9060770B2 (en) | 2003-05-20 | 2015-06-23 | Ethicon Endo-Surgery, Inc. | Robotically-driven surgical instrument with E-beam driver |
US20070084897A1 (en) | 2003-05-20 | 2007-04-19 | Shelton Frederick E Iv | Articulating surgical stapling instrument incorporating a two-piece e-beam firing mechanism |
EP1763703A4 (en) | 2004-05-12 | 2010-12-08 | Massachusetts Inst Technology | Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like |
US8215531B2 (en) | 2004-07-28 | 2012-07-10 | Ethicon Endo-Surgery, Inc. | Surgical stapling instrument having a medical substance dispenser |
US11896225B2 (en) | 2004-07-28 | 2024-02-13 | Cilag Gmbh International | Staple cartridge comprising a pan |
US10159482B2 (en) | 2005-08-31 | 2018-12-25 | Ethicon Llc | Fastener cartridge assembly comprising a fixed anvil and different staple heights |
US11484312B2 (en) | 2005-08-31 | 2022-11-01 | Cilag Gmbh International | Staple cartridge comprising a staple driver arrangement |
US11246590B2 (en) | 2005-08-31 | 2022-02-15 | Cilag Gmbh International | Staple cartridge including staple drivers having different unfired heights |
US9237891B2 (en) | 2005-08-31 | 2016-01-19 | Ethicon Endo-Surgery, Inc. | Robotically-controlled surgical stapling devices that produce formed staples having different lengths |
US7669746B2 (en) | 2005-08-31 | 2010-03-02 | Ethicon Endo-Surgery, Inc. | Staple cartridges for forming staples having differing formed staple heights |
US7934630B2 (en) | 2005-08-31 | 2011-05-03 | Ethicon Endo-Surgery, Inc. | Staple cartridges for forming staples having differing formed staple heights |
US20070106317A1 (en) | 2005-11-09 | 2007-05-10 | Shelton Frederick E Iv | Hydraulically and electrically actuated articulation joints for surgical instruments |
US8820603B2 (en) | 2006-01-31 | 2014-09-02 | Ethicon Endo-Surgery, Inc. | Accessing data stored in a memory of a surgical instrument |
US7753904B2 (en) | 2006-01-31 | 2010-07-13 | Ethicon Endo-Surgery, Inc. | Endoscopic surgical instrument with a handle that can articulate with respect to the shaft |
US20110024477A1 (en) | 2009-02-06 | 2011-02-03 | Hall Steven G | Driven Surgical Stapler Improvements |
US20110295295A1 (en) | 2006-01-31 | 2011-12-01 | Ethicon Endo-Surgery, Inc. | Robotically-controlled surgical instrument having recording capabilities |
US11278279B2 (en) | 2006-01-31 | 2022-03-22 | Cilag Gmbh International | Surgical instrument assembly |
US8186555B2 (en) | 2006-01-31 | 2012-05-29 | Ethicon Endo-Surgery, Inc. | Motor-driven surgical cutting and fastening instrument with mechanical closure system |
US8708213B2 (en) | 2006-01-31 | 2014-04-29 | Ethicon Endo-Surgery, Inc. | Surgical instrument having a feedback system |
US7845537B2 (en) | 2006-01-31 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Surgical instrument having recording capabilities |
US11224427B2 (en) | 2006-01-31 | 2022-01-18 | Cilag Gmbh International | Surgical stapling system including a console and retraction assembly |
US11793518B2 (en) | 2006-01-31 | 2023-10-24 | Cilag Gmbh International | Powered surgical instruments with firing system lockout arrangements |
US20120292367A1 (en) | 2006-01-31 | 2012-11-22 | Ethicon Endo-Surgery, Inc. | Robotically-controlled end effector |
US8992422B2 (en) | 2006-03-23 | 2015-03-31 | Ethicon Endo-Surgery, Inc. | Robotically-controlled endoscopic accessory channel |
US8322455B2 (en) | 2006-06-27 | 2012-12-04 | Ethicon Endo-Surgery, Inc. | Manually driven surgical cutting and fastening instrument |
WO2008005427A2 (en) * | 2006-06-30 | 2008-01-10 | Biomimetic Therapeutics, Inc. | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries |
US10568652B2 (en) | 2006-09-29 | 2020-02-25 | Ethicon Llc | Surgical staples having attached drivers of different heights and stapling instruments for deploying the same |
US20080102123A1 (en) * | 2006-10-27 | 2008-05-01 | Schachter Deborah M | Self-gelling tunable drug delivery system |
MX2009006321A (en) * | 2006-12-13 | 2009-06-30 | Innovaform Technologies Llc | Pesticidal aggregates. |
WO2008086486A1 (en) * | 2007-01-10 | 2008-07-17 | The Regents Of The University Of Michigan | Porous objects having immobilized encapsulated biomolecules |
US8684253B2 (en) | 2007-01-10 | 2014-04-01 | Ethicon Endo-Surgery, Inc. | Surgical instrument with wireless communication between a control unit of a robotic system and remote sensor |
US11291441B2 (en) | 2007-01-10 | 2022-04-05 | Cilag Gmbh International | Surgical instrument with wireless communication between control unit and remote sensor |
US8652120B2 (en) | 2007-01-10 | 2014-02-18 | Ethicon Endo-Surgery, Inc. | Surgical instrument with wireless communication between control unit and sensor transponders |
US11039836B2 (en) | 2007-01-11 | 2021-06-22 | Cilag Gmbh International | Staple cartridge for use with a surgical stapling instrument |
US8827133B2 (en) | 2007-01-11 | 2014-09-09 | Ethicon Endo-Surgery, Inc. | Surgical stapling device having supports for a flexible drive mechanism |
US8916185B2 (en) * | 2007-02-28 | 2014-12-23 | The Regents Of The University Of Michigan | Immobilizing particles onto surfaces |
US7669747B2 (en) | 2007-03-15 | 2010-03-02 | Ethicon Endo-Surgery, Inc. | Washer for use with a surgical stapling instrument |
US8931682B2 (en) | 2007-06-04 | 2015-01-13 | Ethicon Endo-Surgery, Inc. | Robotically-controlled shaft based rotary drive systems for surgical instruments |
US11857181B2 (en) | 2007-06-04 | 2024-01-02 | Cilag Gmbh International | Robotically-controlled shaft based rotary drive systems for surgical instruments |
US7753245B2 (en) | 2007-06-22 | 2010-07-13 | Ethicon Endo-Surgery, Inc. | Surgical stapling instruments |
US11849941B2 (en) | 2007-06-29 | 2023-12-26 | Cilag Gmbh International | Staple cartridge having staple cavities extending at a transverse angle relative to a longitudinal cartridge axis |
US8313527B2 (en) | 2007-11-05 | 2012-11-20 | Allergan, Inc. | Soft prosthesis shell texturing method |
US20090286907A1 (en) * | 2008-01-23 | 2009-11-19 | Beltz Mark W | Fumaric Acid/Diol Polyesters and Their Manufacture and Use |
US7866527B2 (en) | 2008-02-14 | 2011-01-11 | Ethicon Endo-Surgery, Inc. | Surgical stapling apparatus with interlockable firing system |
US9179912B2 (en) | 2008-02-14 | 2015-11-10 | Ethicon Endo-Surgery, Inc. | Robotically-controlled motorized surgical cutting and fastening instrument |
BRPI0901282A2 (en) | 2008-02-14 | 2009-11-17 | Ethicon Endo Surgery Inc | surgical cutting and fixation instrument with rf electrodes |
US8573465B2 (en) | 2008-02-14 | 2013-11-05 | Ethicon Endo-Surgery, Inc. | Robotically-controlled surgical end effector system with rotary actuated closure systems |
US7819298B2 (en) | 2008-02-14 | 2010-10-26 | Ethicon Endo-Surgery, Inc. | Surgical stapling apparatus with control features operable with one hand |
US8636736B2 (en) | 2008-02-14 | 2014-01-28 | Ethicon Endo-Surgery, Inc. | Motorized surgical cutting and fastening instrument |
US8758391B2 (en) | 2008-02-14 | 2014-06-24 | Ethicon Endo-Surgery, Inc. | Interchangeable tools for surgical instruments |
US9770245B2 (en) | 2008-02-15 | 2017-09-26 | Ethicon Llc | Layer arrangements for surgical staple cartridges |
US8048361B2 (en) * | 2008-05-20 | 2011-11-01 | National Taiwan University | Method for forming porous bio-mimicking scaffold |
KR100932949B1 (en) * | 2008-07-14 | 2009-12-21 | 한국기계연구원 | Porous ceramic ball including hierarchically porous structure and the preparation method thereof |
US9050184B2 (en) | 2008-08-13 | 2015-06-09 | Allergan, Inc. | Dual plane breast implant |
US8506627B2 (en) | 2008-08-13 | 2013-08-13 | Allergan, Inc. | Soft filled prosthesis shell with discrete fixation surfaces |
US9386983B2 (en) | 2008-09-23 | 2016-07-12 | Ethicon Endo-Surgery, Llc | Robotically-controlled motorized surgical instrument |
US9005230B2 (en) | 2008-09-23 | 2015-04-14 | Ethicon Endo-Surgery, Inc. | Motorized surgical instrument |
US8210411B2 (en) | 2008-09-23 | 2012-07-03 | Ethicon Endo-Surgery, Inc. | Motor-driven surgical cutting instrument |
US11648005B2 (en) | 2008-09-23 | 2023-05-16 | Cilag Gmbh International | Robotically-controlled motorized surgical instrument with an end effector |
US8608045B2 (en) | 2008-10-10 | 2013-12-17 | Ethicon Endo-Sugery, Inc. | Powered surgical cutting and stapling apparatus with manually retractable firing system |
US8034363B2 (en) | 2008-12-11 | 2011-10-11 | Advanced Technologies And Regenerative Medicine, Llc. | Sustained release systems of ascorbic acid phosphate |
US8517239B2 (en) | 2009-02-05 | 2013-08-27 | Ethicon Endo-Surgery, Inc. | Surgical stapling instrument comprising a magnetic element driver |
CA2751664A1 (en) | 2009-02-06 | 2010-08-12 | Ethicon Endo-Surgery, Inc. | Driven surgical stapler improvements |
DE102009013012A1 (en) * | 2009-03-16 | 2010-09-30 | TransMIT Gesellschaft für Technologietransfer mbH | Therapeutic and diagnostic loaded composite materials comprising polymer nanoparticles and polymer fibers |
US20110093069A1 (en) | 2009-10-16 | 2011-04-21 | Allergan, Inc. | Implants and methdos for manufacturing same |
US8851354B2 (en) | 2009-12-24 | 2014-10-07 | Ethicon Endo-Surgery, Inc. | Surgical cutting instrument that analyzes tissue thickness |
DE102010000043A1 (en) * | 2010-01-11 | 2011-07-14 | Lars 12587 Dähne | Inhaler system for volatile substances |
CA2787824A1 (en) | 2010-01-28 | 2011-08-04 | Allergan, Inc. | Open celled foams, implants including them and processes for making same |
US9138308B2 (en) | 2010-02-03 | 2015-09-22 | Apollo Endosurgery, Inc. | Mucosal tissue adhesion via textured surface |
US9072821B2 (en) | 2010-02-05 | 2015-07-07 | Allergan, Inc. | Biocompatible structures and compositions |
US8889751B2 (en) | 2010-09-28 | 2014-11-18 | Allergan, Inc. | Porous materials, methods of making and uses |
US9044897B2 (en) | 2010-09-28 | 2015-06-02 | Allergan, Inc. | Porous materials, methods of making and uses |
US8877822B2 (en) | 2010-09-28 | 2014-11-04 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
US9205577B2 (en) | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
WO2011137076A1 (en) | 2010-04-27 | 2011-11-03 | Allergan, Inc. | Foam-like materials and methods for producing same |
AU2011252010A1 (en) | 2010-05-10 | 2012-12-20 | Allergan, Inc. | Porous materials, methods of making and uses |
US11202853B2 (en) | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
DK2569021T3 (en) | 2010-05-11 | 2017-04-10 | Allergan Inc | POROGENE COMPOSITIONS, PROCEDURES FOR MANUFACTURING AND APPLICATIONS |
ES2723074T3 (en) | 2010-05-11 | 2019-08-21 | Allergan Inc | Porous materials, preparation methods and uses |
US8783543B2 (en) | 2010-07-30 | 2014-07-22 | Ethicon Endo-Surgery, Inc. | Tissue acquisition arrangements and methods for surgical stapling devices |
US9320523B2 (en) | 2012-03-28 | 2016-04-26 | Ethicon Endo-Surgery, Llc | Tissue thickness compensator comprising tissue ingrowth features |
US11812965B2 (en) | 2010-09-30 | 2023-11-14 | Cilag Gmbh International | Layer of material for a surgical end effector |
US8978954B2 (en) | 2010-09-30 | 2015-03-17 | Ethicon Endo-Surgery, Inc. | Staple cartridge comprising an adjustable distal portion |
US11298125B2 (en) | 2010-09-30 | 2022-04-12 | Cilag Gmbh International | Tissue stapler having a thickness compensator |
US9592050B2 (en) | 2010-09-30 | 2017-03-14 | Ethicon Endo-Surgery, Llc | End effector comprising a distal tissue abutment member |
US9351730B2 (en) | 2011-04-29 | 2016-05-31 | Ethicon Endo-Surgery, Llc | Tissue thickness compensator comprising channels |
US9629814B2 (en) | 2010-09-30 | 2017-04-25 | Ethicon Endo-Surgery, Llc | Tissue thickness compensator configured to redistribute compressive forces |
US10945731B2 (en) | 2010-09-30 | 2021-03-16 | Ethicon Llc | Tissue thickness compensator comprising controlled release and expansion |
US11849952B2 (en) | 2010-09-30 | 2023-12-26 | Cilag Gmbh International | Staple cartridge comprising staples positioned within a compressible portion thereof |
US8695866B2 (en) | 2010-10-01 | 2014-04-15 | Ethicon Endo-Surgery, Inc. | Surgical instrument having a power control circuit |
US8679279B2 (en) | 2010-11-16 | 2014-03-25 | Allergan, Inc. | Methods for creating foam-like texture |
US8546458B2 (en) | 2010-12-07 | 2013-10-01 | Allergan, Inc. | Process for texturing materials |
US20120202239A1 (en) * | 2011-02-04 | 2012-08-09 | Ezekiel Kruglick | Materials, monitoring, and controlling tissue growth using magnetic nanoparticles |
CA2834649C (en) | 2011-04-29 | 2021-02-16 | Ethicon Endo-Surgery, Inc. | Staple cartridge comprising staples positioned within a compressible portion thereof |
US9072535B2 (en) | 2011-05-27 | 2015-07-07 | Ethicon Endo-Surgery, Inc. | Surgical stapling instruments with rotatable staple deployment arrangements |
US11207064B2 (en) | 2011-05-27 | 2021-12-28 | Cilag Gmbh International | Automated end effector component reloading system for use with a robotic system |
CN102389756B (en) * | 2011-08-11 | 2014-01-01 | 长春金赛药业有限责任公司 | Method for preparing micro spheres by multiple emulsion process |
US8801782B2 (en) | 2011-12-15 | 2014-08-12 | Allergan, Inc. | Surgical methods for breast reconstruction or augmentation |
WO2013134360A1 (en) * | 2012-03-06 | 2013-09-12 | The Uab Research Foundation | Technologies for pancreatic islet transplantation |
JP6305979B2 (en) | 2012-03-28 | 2018-04-04 | エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. | Tissue thickness compensator with multiple layers |
CN104334098B (en) | 2012-03-28 | 2017-03-22 | 伊西康内外科公司 | Tissue thickness compensator comprising capsules defining a low pressure environment |
JP6224070B2 (en) | 2012-03-28 | 2017-11-01 | エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. | Retainer assembly including tissue thickness compensator |
US9101358B2 (en) | 2012-06-15 | 2015-08-11 | Ethicon Endo-Surgery, Inc. | Articulatable surgical instrument comprising a firing drive |
US20140001231A1 (en) | 2012-06-28 | 2014-01-02 | Ethicon Endo-Surgery, Inc. | Firing system lockout arrangements for surgical instruments |
US20140001234A1 (en) | 2012-06-28 | 2014-01-02 | Ethicon Endo-Surgery, Inc. | Coupling arrangements for attaching surgical end effectors to drive systems therefor |
US11278284B2 (en) | 2012-06-28 | 2022-03-22 | Cilag Gmbh International | Rotary drive arrangements for surgical instruments |
US9649111B2 (en) | 2012-06-28 | 2017-05-16 | Ethicon Endo-Surgery, Llc | Replaceable clip cartridge for a clip applier |
US9289256B2 (en) | 2012-06-28 | 2016-03-22 | Ethicon Endo-Surgery, Llc | Surgical end effectors having angled tissue-contacting surfaces |
CN104487005B (en) | 2012-06-28 | 2017-09-08 | 伊西康内外科公司 | Empty squeeze latching member |
BR112014032776B1 (en) | 2012-06-28 | 2021-09-08 | Ethicon Endo-Surgery, Inc | SURGICAL INSTRUMENT SYSTEM AND SURGICAL KIT FOR USE WITH A SURGICAL INSTRUMENT SYSTEM |
WO2014027254A1 (en) * | 2012-08-14 | 2014-02-20 | Wockhardt Limited | Pharmaceutical microparticulate compositions of polypeptides |
EP2897658A1 (en) | 2012-09-24 | 2015-07-29 | Allergan, Inc. | Porous materials, methods of making and uses |
EP2931490A1 (en) | 2012-12-13 | 2015-10-21 | Allergan, Inc. | Device and method for making a variable surface breast implant |
MX364729B (en) | 2013-03-01 | 2019-05-06 | Ethicon Endo Surgery Inc | Surgical instrument with a soft stop. |
MX368026B (en) | 2013-03-01 | 2019-09-12 | Ethicon Endo Surgery Inc | Articulatable surgical instruments with conductive pathways for signal communication. |
US9629629B2 (en) | 2013-03-14 | 2017-04-25 | Ethicon Endo-Surgey, LLC | Control systems for surgical instruments |
US9629623B2 (en) | 2013-03-14 | 2017-04-25 | Ethicon Endo-Surgery, Llc | Drive system lockout arrangements for modular surgical instruments |
US10405857B2 (en) | 2013-04-16 | 2019-09-10 | Ethicon Llc | Powered linear surgical stapler |
BR112015026109B1 (en) | 2013-04-16 | 2022-02-22 | Ethicon Endo-Surgery, Inc | surgical instrument |
CN106028966B (en) | 2013-08-23 | 2018-06-22 | 伊西康内外科有限责任公司 | For the firing member restoring device of powered surgical instrument |
US9808249B2 (en) | 2013-08-23 | 2017-11-07 | Ethicon Llc | Attachment portions for surgical instrument assemblies |
US9962161B2 (en) | 2014-02-12 | 2018-05-08 | Ethicon Llc | Deliverable surgical instrument |
EP3110451B1 (en) * | 2014-02-26 | 2020-08-19 | University of Massachusetts Medical School | Amphiphilic degradable polymers for immobilization and sustained delivery of biomolecules |
BR112016021943B1 (en) | 2014-03-26 | 2022-06-14 | Ethicon Endo-Surgery, Llc | SURGICAL INSTRUMENT FOR USE BY AN OPERATOR IN A SURGICAL PROCEDURE |
US9820738B2 (en) | 2014-03-26 | 2017-11-21 | Ethicon Llc | Surgical instrument comprising interactive systems |
US9733663B2 (en) | 2014-03-26 | 2017-08-15 | Ethicon Llc | Power management through segmented circuit and variable voltage protection |
US20150297225A1 (en) | 2014-04-16 | 2015-10-22 | Ethicon Endo-Surgery, Inc. | Fastener cartridges including extensions having different configurations |
BR112016023807B1 (en) | 2014-04-16 | 2022-07-12 | Ethicon Endo-Surgery, Llc | CARTRIDGE SET OF FASTENERS FOR USE WITH A SURGICAL INSTRUMENT |
BR112016023825B1 (en) | 2014-04-16 | 2022-08-02 | Ethicon Endo-Surgery, Llc | STAPLE CARTRIDGE FOR USE WITH A SURGICAL STAPLER AND STAPLE CARTRIDGE FOR USE WITH A SURGICAL INSTRUMENT |
US10299792B2 (en) | 2014-04-16 | 2019-05-28 | Ethicon Llc | Fastener cartridge comprising non-uniform fasteners |
CN106456176B (en) | 2014-04-16 | 2019-06-28 | 伊西康内外科有限责任公司 | Fastener cartridge including the extension with various configuration |
US9486309B2 (en) | 2014-04-25 | 2016-11-08 | Allergan, Inc. | Lighter weight implant |
US10092392B2 (en) | 2014-05-16 | 2018-10-09 | Allergan, Inc. | Textured breast implant and methods of making same |
US9539086B2 (en) | 2014-05-16 | 2017-01-10 | Allergan, Inc. | Soft filled prosthesis shell with variable texture |
US10135242B2 (en) | 2014-09-05 | 2018-11-20 | Ethicon Llc | Smart cartridge wake up operation and data retention |
BR112017004361B1 (en) | 2014-09-05 | 2023-04-11 | Ethicon Llc | ELECTRONIC SYSTEM FOR A SURGICAL INSTRUMENT |
US11311294B2 (en) | 2014-09-05 | 2022-04-26 | Cilag Gmbh International | Powered medical device including measurement of closure state of jaws |
US10105142B2 (en) | 2014-09-18 | 2018-10-23 | Ethicon Llc | Surgical stapler with plurality of cutting elements |
CN107427300B (en) | 2014-09-26 | 2020-12-04 | 伊西康有限责任公司 | Surgical suture buttress and buttress material |
US11523821B2 (en) | 2014-09-26 | 2022-12-13 | Cilag Gmbh International | Method for creating a flexible staple line |
US9862807B2 (en) * | 2014-10-06 | 2018-01-09 | The Regents Of The University Of Michigan | Nanofibrous spongy microspheres |
US10076325B2 (en) | 2014-10-13 | 2018-09-18 | Ethicon Llc | Surgical stapling apparatus comprising a tissue stop |
US9924944B2 (en) | 2014-10-16 | 2018-03-27 | Ethicon Llc | Staple cartridge comprising an adjunct material |
US10517594B2 (en) | 2014-10-29 | 2019-12-31 | Ethicon Llc | Cartridge assemblies for surgical staplers |
US11141153B2 (en) | 2014-10-29 | 2021-10-12 | Cilag Gmbh International | Staple cartridges comprising driver arrangements |
US9844376B2 (en) | 2014-11-06 | 2017-12-19 | Ethicon Llc | Staple cartridge comprising a releasable adjunct material |
WO2016081541A1 (en) | 2014-11-19 | 2016-05-26 | The Research Foundation For The State University Of New York | Nanostructured fibrous membranes for membrane distillation |
US10736636B2 (en) | 2014-12-10 | 2020-08-11 | Ethicon Llc | Articulatable surgical instrument system |
US9987000B2 (en) | 2014-12-18 | 2018-06-05 | Ethicon Llc | Surgical instrument assembly comprising a flexible articulation system |
US9844375B2 (en) | 2014-12-18 | 2017-12-19 | Ethicon Llc | Drive arrangements for articulatable surgical instruments |
US9844374B2 (en) | 2014-12-18 | 2017-12-19 | Ethicon Llc | Surgical instrument systems comprising an articulatable end effector and means for adjusting the firing stroke of a firing member |
US9968355B2 (en) | 2014-12-18 | 2018-05-15 | Ethicon Llc | Surgical instruments with articulatable end effectors and improved firing beam support arrangements |
US10085748B2 (en) | 2014-12-18 | 2018-10-02 | Ethicon Llc | Locking arrangements for detachable shaft assemblies with articulatable surgical end effectors |
BR112017012996B1 (en) | 2014-12-18 | 2022-11-08 | Ethicon Llc | SURGICAL INSTRUMENT WITH AN ANvil WHICH IS SELECTIVELY MOVABLE ABOUT AN IMMOVABLE GEOMETRIC AXIS DIFFERENT FROM A STAPLE CARTRIDGE |
US20160220498A1 (en) * | 2015-01-29 | 2016-08-04 | Aneesh SONI | Fully or partially biodegradable device for controlled drug delivery |
US11154301B2 (en) | 2015-02-27 | 2021-10-26 | Cilag Gmbh International | Modular stapling assembly |
JP2020121162A (en) | 2015-03-06 | 2020-08-13 | エシコン エルエルシーEthicon LLC | Time dependent evaluation of sensor data to determine stability element, creep element and viscoelastic element of measurement |
US10548504B2 (en) | 2015-03-06 | 2020-02-04 | Ethicon Llc | Overlaid multi sensor radio frequency (RF) electrode system to measure tissue compression |
US10441279B2 (en) | 2015-03-06 | 2019-10-15 | Ethicon Llc | Multiple level thresholds to modify operation of powered surgical instruments |
US10245033B2 (en) | 2015-03-06 | 2019-04-02 | Ethicon Llc | Surgical instrument comprising a lockable battery housing |
US9993248B2 (en) | 2015-03-06 | 2018-06-12 | Ethicon Endo-Surgery, Llc | Smart sensors with local signal processing |
US9901342B2 (en) | 2015-03-06 | 2018-02-27 | Ethicon Endo-Surgery, Llc | Signal and power communication system positioned on a rotatable shaft |
US10390825B2 (en) | 2015-03-31 | 2019-08-27 | Ethicon Llc | Surgical instrument with progressive rotary drive systems |
US10617418B2 (en) | 2015-08-17 | 2020-04-14 | Ethicon Llc | Implantable layers for a surgical instrument |
US10105139B2 (en) | 2015-09-23 | 2018-10-23 | Ethicon Llc | Surgical stapler having downstream current-based motor control |
US10238386B2 (en) | 2015-09-23 | 2019-03-26 | Ethicon Llc | Surgical stapler having motor control based on an electrical parameter related to a motor current |
US10299878B2 (en) | 2015-09-25 | 2019-05-28 | Ethicon Llc | Implantable adjunct systems for determining adjunct skew |
US10524788B2 (en) | 2015-09-30 | 2020-01-07 | Ethicon Llc | Compressible adjunct with attachment regions |
US11890015B2 (en) | 2015-09-30 | 2024-02-06 | Cilag Gmbh International | Compressible adjunct with crossing spacer fibers |
US10980539B2 (en) | 2015-09-30 | 2021-04-20 | Ethicon Llc | Implantable adjunct comprising bonded layers |
US10271849B2 (en) | 2015-09-30 | 2019-04-30 | Ethicon Llc | Woven constructs with interlocked standing fibers |
CN108698075A (en) * | 2015-11-30 | 2018-10-23 | 戴垄科技股份有限公司 | Can in wet environment waterproof, resistance to steam and conduction electric device and its manufacturing method |
US10292704B2 (en) | 2015-12-30 | 2019-05-21 | Ethicon Llc | Mechanisms for compensating for battery pack failure in powered surgical instruments |
US10265068B2 (en) | 2015-12-30 | 2019-04-23 | Ethicon Llc | Surgical instruments with separable motors and motor control circuits |
US10368865B2 (en) | 2015-12-30 | 2019-08-06 | Ethicon Llc | Mechanisms for compensating for drivetrain failure in powered surgical instruments |
US11213293B2 (en) | 2016-02-09 | 2022-01-04 | Cilag Gmbh International | Articulatable surgical instruments with single articulation link arrangements |
CN108882932B (en) | 2016-02-09 | 2021-07-23 | 伊西康有限责任公司 | Surgical instrument with asymmetric articulation configuration |
US10448948B2 (en) | 2016-02-12 | 2019-10-22 | Ethicon Llc | Mechanisms for compensating for drivetrain failure in powered surgical instruments |
US11224426B2 (en) | 2016-02-12 | 2022-01-18 | Cilag Gmbh International | Mechanisms for compensating for drivetrain failure in powered surgical instruments |
WO2017152112A2 (en) * | 2016-03-03 | 2017-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hydrogel systems for skeletal interfacial tissue regeneration applied to epiphyseal growth plate repair |
US10426467B2 (en) | 2016-04-15 | 2019-10-01 | Ethicon Llc | Surgical instrument with detection sensors |
US10492783B2 (en) | 2016-04-15 | 2019-12-03 | Ethicon, Llc | Surgical instrument with improved stop/start control during a firing motion |
US10335145B2 (en) | 2016-04-15 | 2019-07-02 | Ethicon Llc | Modular surgical instrument with configurable operating mode |
US10357247B2 (en) | 2016-04-15 | 2019-07-23 | Ethicon Llc | Surgical instrument with multiple program responses during a firing motion |
US11179150B2 (en) | 2016-04-15 | 2021-11-23 | Cilag Gmbh International | Systems and methods for controlling a surgical stapling and cutting instrument |
US10828028B2 (en) | 2016-04-15 | 2020-11-10 | Ethicon Llc | Surgical instrument with multiple program responses during a firing motion |
US11607239B2 (en) | 2016-04-15 | 2023-03-21 | Cilag Gmbh International | Systems and methods for controlling a surgical stapling and cutting instrument |
US10456137B2 (en) | 2016-04-15 | 2019-10-29 | Ethicon Llc | Staple formation detection mechanisms |
US20170296173A1 (en) | 2016-04-18 | 2017-10-19 | Ethicon Endo-Surgery, Llc | Method for operating a surgical instrument |
US10363037B2 (en) | 2016-04-18 | 2019-07-30 | Ethicon Llc | Surgical instrument system comprising a magnetic lockout |
US11317917B2 (en) | 2016-04-18 | 2022-05-03 | Cilag Gmbh International | Surgical stapling system comprising a lockable firing assembly |
US10035193B2 (en) * | 2016-08-18 | 2018-07-31 | AhuraTech LLC | Method for synthesizing particles in the presence of a solid phase |
US10259999B2 (en) * | 2016-08-18 | 2019-04-16 | AhuraTech LLC | Method for storing and releasing nanoparticles |
EP3293253A1 (en) * | 2016-09-13 | 2018-03-14 | Carroucell | Process for producing a glass macroporous matrix and uses |
US20180168625A1 (en) | 2016-12-21 | 2018-06-21 | Ethicon Endo-Surgery, Llc | Surgical stapling instruments with smart staple cartridges |
US10980536B2 (en) | 2016-12-21 | 2021-04-20 | Ethicon Llc | No-cartridge and spent cartridge lockout arrangements for surgical staplers |
US10736629B2 (en) | 2016-12-21 | 2020-08-11 | Ethicon Llc | Surgical tool assemblies with clutching arrangements for shifting between closure systems with closure stroke reduction features and articulation and firing systems |
US10537325B2 (en) | 2016-12-21 | 2020-01-21 | Ethicon Llc | Staple forming pocket arrangement to accommodate different types of staples |
US20180168598A1 (en) | 2016-12-21 | 2018-06-21 | Ethicon Endo-Surgery, Llc | Staple forming pocket arrangements comprising zoned forming surface grooves |
US20180168575A1 (en) | 2016-12-21 | 2018-06-21 | Ethicon Endo-Surgery, Llc | Surgical stapling systems |
JP7010956B2 (en) | 2016-12-21 | 2022-01-26 | エシコン エルエルシー | How to staple tissue |
US10492785B2 (en) | 2016-12-21 | 2019-12-03 | Ethicon Llc | Shaft assembly comprising a lockout |
US20180168615A1 (en) | 2016-12-21 | 2018-06-21 | Ethicon Endo-Surgery, Llc | Method of deforming staples from two different types of staple cartridges with the same surgical stapling instrument |
MX2019007311A (en) | 2016-12-21 | 2019-11-18 | Ethicon Llc | Surgical stapling systems. |
US11134942B2 (en) | 2016-12-21 | 2021-10-05 | Cilag Gmbh International | Surgical stapling instruments and staple-forming anvils |
US11419606B2 (en) | 2016-12-21 | 2022-08-23 | Cilag Gmbh International | Shaft assembly comprising a clutch configured to adapt the output of a rotary firing member to two different systems |
JP6983893B2 (en) | 2016-12-21 | 2021-12-17 | エシコン エルエルシーEthicon LLC | Lockout configuration for surgical end effectors and replaceable tool assemblies |
US10485543B2 (en) | 2016-12-21 | 2019-11-26 | Ethicon Llc | Anvil having a knife slot width |
US10568625B2 (en) | 2016-12-21 | 2020-02-25 | Ethicon Llc | Staple cartridges and arrangements of staples and staple cavities therein |
US10973516B2 (en) | 2016-12-21 | 2021-04-13 | Ethicon Llc | Surgical end effectors and adaptable firing members therefor |
US10779820B2 (en) | 2017-06-20 | 2020-09-22 | Ethicon Llc | Systems and methods for controlling motor speed according to user input for a surgical instrument |
US10881399B2 (en) | 2017-06-20 | 2021-01-05 | Ethicon Llc | Techniques for adaptive control of motor velocity of a surgical stapling and cutting instrument |
US11071554B2 (en) | 2017-06-20 | 2021-07-27 | Cilag Gmbh International | Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on magnitude of velocity error measurements |
US10307170B2 (en) | 2017-06-20 | 2019-06-04 | Ethicon Llc | Method for closed loop control of motor velocity of a surgical stapling and cutting instrument |
US10888321B2 (en) | 2017-06-20 | 2021-01-12 | Ethicon Llc | Systems and methods for controlling velocity of a displacement member of a surgical stapling and cutting instrument |
US10980537B2 (en) | 2017-06-20 | 2021-04-20 | Ethicon Llc | Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified number of shaft rotations |
US11090046B2 (en) | 2017-06-20 | 2021-08-17 | Cilag Gmbh International | Systems and methods for controlling displacement member motion of a surgical stapling and cutting instrument |
US11653914B2 (en) | 2017-06-20 | 2023-05-23 | Cilag Gmbh International | Systems and methods for controlling motor velocity of a surgical stapling and cutting instrument according to articulation angle of end effector |
US11517325B2 (en) | 2017-06-20 | 2022-12-06 | Cilag Gmbh International | Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured displacement distance traveled over a specified time interval |
US11382638B2 (en) | 2017-06-20 | 2022-07-12 | Cilag Gmbh International | Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified displacement distance |
US11266405B2 (en) | 2017-06-27 | 2022-03-08 | Cilag Gmbh International | Surgical anvil manufacturing methods |
US10993716B2 (en) | 2017-06-27 | 2021-05-04 | Ethicon Llc | Surgical anvil arrangements |
US10631859B2 (en) | 2017-06-27 | 2020-04-28 | Ethicon Llc | Articulation systems for surgical instruments |
US11324503B2 (en) | 2017-06-27 | 2022-05-10 | Cilag Gmbh International | Surgical firing member arrangements |
US11259805B2 (en) | 2017-06-28 | 2022-03-01 | Cilag Gmbh International | Surgical instrument comprising firing member supports |
US10903685B2 (en) | 2017-06-28 | 2021-01-26 | Ethicon Llc | Surgical shaft assemblies with slip ring assemblies forming capacitive channels |
USD906355S1 (en) | 2017-06-28 | 2020-12-29 | Ethicon Llc | Display screen or portion thereof with a graphical user interface for a surgical instrument |
US11389161B2 (en) | 2017-06-28 | 2022-07-19 | Cilag Gmbh International | Surgical instrument comprising selectively actuatable rotatable couplers |
US11246592B2 (en) | 2017-06-28 | 2022-02-15 | Cilag Gmbh International | Surgical instrument comprising an articulation system lockable to a frame |
US10765427B2 (en) | 2017-06-28 | 2020-09-08 | Ethicon Llc | Method for articulating a surgical instrument |
US10588633B2 (en) | 2017-06-28 | 2020-03-17 | Ethicon Llc | Surgical instruments with open and closable jaws and axially movable firing member that is initially parked in close proximity to the jaws prior to firing |
EP3420947B1 (en) | 2017-06-28 | 2022-05-25 | Cilag GmbH International | Surgical instrument comprising selectively actuatable rotatable couplers |
US11564686B2 (en) | 2017-06-28 | 2023-01-31 | Cilag Gmbh International | Surgical shaft assemblies with flexible interfaces |
US10932772B2 (en) | 2017-06-29 | 2021-03-02 | Ethicon Llc | Methods for closed loop velocity control for robotic surgical instrument |
US11304695B2 (en) | 2017-08-03 | 2022-04-19 | Cilag Gmbh International | Surgical system shaft interconnection |
US11471155B2 (en) | 2017-08-03 | 2022-10-18 | Cilag Gmbh International | Surgical system bailout |
US11944300B2 (en) | 2017-08-03 | 2024-04-02 | Cilag Gmbh International | Method for operating a surgical system bailout |
USD907648S1 (en) | 2017-09-29 | 2021-01-12 | Ethicon Llc | Display screen or portion thereof with animated graphical user interface |
USD907647S1 (en) | 2017-09-29 | 2021-01-12 | Ethicon Llc | Display screen or portion thereof with animated graphical user interface |
USD917500S1 (en) | 2017-09-29 | 2021-04-27 | Ethicon Llc | Display screen or portion thereof with graphical user interface |
US11399829B2 (en) | 2017-09-29 | 2022-08-02 | Cilag Gmbh International | Systems and methods of initiating a power shutdown mode for a surgical instrument |
US11090075B2 (en) | 2017-10-30 | 2021-08-17 | Cilag Gmbh International | Articulation features for surgical end effector |
US11134944B2 (en) | 2017-10-30 | 2021-10-05 | Cilag Gmbh International | Surgical stapler knife motion controls |
US10842490B2 (en) | 2017-10-31 | 2020-11-24 | Ethicon Llc | Cartridge body design with force reduction based on firing completion |
US10779826B2 (en) | 2017-12-15 | 2020-09-22 | Ethicon Llc | Methods of operating surgical end effectors |
US10966718B2 (en) | 2017-12-15 | 2021-04-06 | Ethicon Llc | Dynamic clamping assemblies with improved wear characteristics for use in connection with electromechanical surgical instruments |
US10743875B2 (en) | 2017-12-15 | 2020-08-18 | Ethicon Llc | Surgical end effectors with jaw stiffener arrangements configured to permit monitoring of firing member |
US11071543B2 (en) | 2017-12-15 | 2021-07-27 | Cilag Gmbh International | Surgical end effectors with clamping assemblies configured to increase jaw aperture ranges |
US11033267B2 (en) | 2017-12-15 | 2021-06-15 | Ethicon Llc | Systems and methods of controlling a clamping member firing rate of a surgical instrument |
US10828033B2 (en) | 2017-12-15 | 2020-11-10 | Ethicon Llc | Handheld electromechanical surgical instruments with improved motor control arrangements for positioning components of an adapter coupled thereto |
US10869666B2 (en) | 2017-12-15 | 2020-12-22 | Ethicon Llc | Adapters with control systems for controlling multiple motors of an electromechanical surgical instrument |
US10779825B2 (en) | 2017-12-15 | 2020-09-22 | Ethicon Llc | Adapters with end effector position sensing and control arrangements for use in connection with electromechanical surgical instruments |
US11197670B2 (en) | 2017-12-15 | 2021-12-14 | Cilag Gmbh International | Surgical end effectors with pivotal jaws configured to touch at their respective distal ends when fully closed |
US11020112B2 (en) | 2017-12-19 | 2021-06-01 | Ethicon Llc | Surgical tools configured for interchangeable use with different controller interfaces |
USD910847S1 (en) | 2017-12-19 | 2021-02-16 | Ethicon Llc | Surgical instrument assembly |
US10729509B2 (en) | 2017-12-19 | 2020-08-04 | Ethicon Llc | Surgical instrument comprising closure and firing locking mechanism |
US10835330B2 (en) | 2017-12-19 | 2020-11-17 | Ethicon Llc | Method for determining the position of a rotatable jaw of a surgical instrument attachment assembly |
US11311290B2 (en) | 2017-12-21 | 2022-04-26 | Cilag Gmbh International | Surgical instrument comprising an end effector dampener |
US11076853B2 (en) | 2017-12-21 | 2021-08-03 | Cilag Gmbh International | Systems and methods of displaying a knife position during transection for a surgical instrument |
US11751867B2 (en) | 2017-12-21 | 2023-09-12 | Cilag Gmbh International | Surgical instrument comprising sequenced systems |
US11129680B2 (en) | 2017-12-21 | 2021-09-28 | Cilag Gmbh International | Surgical instrument comprising a projector |
CN108578393B (en) * | 2018-05-15 | 2021-05-28 | 上海市伤骨科研究所 | Drug permeation-promoted drug-loaded electro-spun fibrous membrane and preparation method thereof |
US11253256B2 (en) | 2018-08-20 | 2022-02-22 | Cilag Gmbh International | Articulatable motor powered surgical instruments with dedicated articulation motor arrangements |
US10856870B2 (en) | 2018-08-20 | 2020-12-08 | Ethicon Llc | Switching arrangements for motor powered articulatable surgical instruments |
US11083458B2 (en) | 2018-08-20 | 2021-08-10 | Cilag Gmbh International | Powered surgical instruments with clutching arrangements to convert linear drive motions to rotary drive motions |
US11324501B2 (en) | 2018-08-20 | 2022-05-10 | Cilag Gmbh International | Surgical stapling devices with improved closure members |
US11207065B2 (en) | 2018-08-20 | 2021-12-28 | Cilag Gmbh International | Method for fabricating surgical stapler anvils |
US10912559B2 (en) | 2018-08-20 | 2021-02-09 | Ethicon Llc | Reinforced deformable anvil tip for surgical stapler anvil |
US11045192B2 (en) | 2018-08-20 | 2021-06-29 | Cilag Gmbh International | Fabricating techniques for surgical stapler anvils |
USD914878S1 (en) | 2018-08-20 | 2021-03-30 | Ethicon Llc | Surgical instrument anvil |
US11039834B2 (en) | 2018-08-20 | 2021-06-22 | Cilag Gmbh International | Surgical stapler anvils with staple directing protrusions and tissue stability features |
US11291440B2 (en) | 2018-08-20 | 2022-04-05 | Cilag Gmbh International | Method for operating a powered articulatable surgical instrument |
CN109620809A (en) * | 2019-02-25 | 2019-04-16 | 李潇 | A kind of preparation method of Instant Gefitinib tablet medicament composition |
CN109967042B (en) * | 2019-03-18 | 2020-07-07 | 浙江大学 | Alkali-soluble chitosan-based aerogel adsorption material prepared by emulsion template method |
US11147551B2 (en) | 2019-03-25 | 2021-10-19 | Cilag Gmbh International | Firing drive arrangements for surgical systems |
US11147553B2 (en) | 2019-03-25 | 2021-10-19 | Cilag Gmbh International | Firing drive arrangements for surgical systems |
US11172929B2 (en) | 2019-03-25 | 2021-11-16 | Cilag Gmbh International | Articulation drive arrangements for surgical systems |
US11696761B2 (en) | 2019-03-25 | 2023-07-11 | Cilag Gmbh International | Firing drive arrangements for surgical systems |
US11648009B2 (en) | 2019-04-30 | 2023-05-16 | Cilag Gmbh International | Rotatable jaw tip for a surgical instrument |
US11426251B2 (en) | 2019-04-30 | 2022-08-30 | Cilag Gmbh International | Articulation directional lights on a surgical instrument |
US11432816B2 (en) | 2019-04-30 | 2022-09-06 | Cilag Gmbh International | Articulation pin for a surgical instrument |
US11903581B2 (en) | 2019-04-30 | 2024-02-20 | Cilag Gmbh International | Methods for stapling tissue using a surgical instrument |
US11253254B2 (en) | 2019-04-30 | 2022-02-22 | Cilag Gmbh International | Shaft rotation actuator on a surgical instrument |
US11471157B2 (en) | 2019-04-30 | 2022-10-18 | Cilag Gmbh International | Articulation control mapping for a surgical instrument |
US11452528B2 (en) | 2019-04-30 | 2022-09-27 | Cilag Gmbh International | Articulation actuators for a surgical instrument |
US11497492B2 (en) | 2019-06-28 | 2022-11-15 | Cilag Gmbh International | Surgical instrument including an articulation lock |
US11219455B2 (en) | 2019-06-28 | 2022-01-11 | Cilag Gmbh International | Surgical instrument including a lockout key |
US11051807B2 (en) | 2019-06-28 | 2021-07-06 | Cilag Gmbh International | Packaging assembly including a particulate trap |
US11241235B2 (en) | 2019-06-28 | 2022-02-08 | Cilag Gmbh International | Method of using multiple RFID chips with a surgical assembly |
US11259803B2 (en) | 2019-06-28 | 2022-03-01 | Cilag Gmbh International | Surgical stapling system having an information encryption protocol |
US11553971B2 (en) | 2019-06-28 | 2023-01-17 | Cilag Gmbh International | Surgical RFID assemblies for display and communication |
US11399837B2 (en) | 2019-06-28 | 2022-08-02 | Cilag Gmbh International | Mechanisms for motor control adjustments of a motorized surgical instrument |
US11627959B2 (en) | 2019-06-28 | 2023-04-18 | Cilag Gmbh International | Surgical instruments including manual and powered system lockouts |
US11246678B2 (en) | 2019-06-28 | 2022-02-15 | Cilag Gmbh International | Surgical stapling system having a frangible RFID tag |
US11291451B2 (en) | 2019-06-28 | 2022-04-05 | Cilag Gmbh International | Surgical instrument with battery compatibility verification functionality |
US11523822B2 (en) | 2019-06-28 | 2022-12-13 | Cilag Gmbh International | Battery pack including a circuit interrupter |
US11660163B2 (en) | 2019-06-28 | 2023-05-30 | Cilag Gmbh International | Surgical system with RFID tags for updating motor assembly parameters |
US11376098B2 (en) | 2019-06-28 | 2022-07-05 | Cilag Gmbh International | Surgical instrument system comprising an RFID system |
US11638587B2 (en) | 2019-06-28 | 2023-05-02 | Cilag Gmbh International | RFID identification systems for surgical instruments |
US11684434B2 (en) | 2019-06-28 | 2023-06-27 | Cilag Gmbh International | Surgical RFID assemblies for instrument operational setting control |
US11771419B2 (en) | 2019-06-28 | 2023-10-03 | Cilag Gmbh International | Packaging for a replaceable component of a surgical stapling system |
US11298127B2 (en) | 2019-06-28 | 2022-04-12 | Cilag GmbH Interational | Surgical stapling system having a lockout mechanism for an incompatible cartridge |
US11298132B2 (en) | 2019-06-28 | 2022-04-12 | Cilag GmbH Inlernational | Staple cartridge including a honeycomb extension |
US11464601B2 (en) | 2019-06-28 | 2022-10-11 | Cilag Gmbh International | Surgical instrument comprising an RFID system for tracking a movable component |
US11426167B2 (en) | 2019-06-28 | 2022-08-30 | Cilag Gmbh International | Mechanisms for proper anvil attachment surgical stapling head assembly |
US11224497B2 (en) | 2019-06-28 | 2022-01-18 | Cilag Gmbh International | Surgical systems with multiple RFID tags |
US11478241B2 (en) | 2019-06-28 | 2022-10-25 | Cilag Gmbh International | Staple cartridge including projections |
US11304696B2 (en) | 2019-12-19 | 2022-04-19 | Cilag Gmbh International | Surgical instrument comprising a powered articulation system |
US11464512B2 (en) | 2019-12-19 | 2022-10-11 | Cilag Gmbh International | Staple cartridge comprising a curved deck surface |
US11529139B2 (en) | 2019-12-19 | 2022-12-20 | Cilag Gmbh International | Motor driven surgical instrument |
US11529137B2 (en) | 2019-12-19 | 2022-12-20 | Cilag Gmbh International | Staple cartridge comprising driver retention members |
US11504122B2 (en) | 2019-12-19 | 2022-11-22 | Cilag Gmbh International | Surgical instrument comprising a nested firing member |
US11576672B2 (en) | 2019-12-19 | 2023-02-14 | Cilag Gmbh International | Surgical instrument comprising a closure system including a closure member and an opening member driven by a drive screw |
US11291447B2 (en) | 2019-12-19 | 2022-04-05 | Cilag Gmbh International | Stapling instrument comprising independent jaw closing and staple firing systems |
US11559304B2 (en) | 2019-12-19 | 2023-01-24 | Cilag Gmbh International | Surgical instrument comprising a rapid closure mechanism |
US11607219B2 (en) | 2019-12-19 | 2023-03-21 | Cilag Gmbh International | Staple cartridge comprising a detachable tissue cutting knife |
US11701111B2 (en) | 2019-12-19 | 2023-07-18 | Cilag Gmbh International | Method for operating a surgical stapling instrument |
US11446029B2 (en) | 2019-12-19 | 2022-09-20 | Cilag Gmbh International | Staple cartridge comprising projections extending from a curved deck surface |
US11911032B2 (en) | 2019-12-19 | 2024-02-27 | Cilag Gmbh International | Staple cartridge comprising a seating cam |
US11234698B2 (en) | 2019-12-19 | 2022-02-01 | Cilag Gmbh International | Stapling system comprising a clamp lockout and a firing lockout |
US11931033B2 (en) | 2019-12-19 | 2024-03-19 | Cilag Gmbh International | Staple cartridge comprising a latch lockout |
US11844520B2 (en) | 2019-12-19 | 2023-12-19 | Cilag Gmbh International | Staple cartridge comprising driver retention members |
USD975851S1 (en) | 2020-06-02 | 2023-01-17 | Cilag Gmbh International | Staple cartridge |
USD974560S1 (en) | 2020-06-02 | 2023-01-03 | Cilag Gmbh International | Staple cartridge |
USD975850S1 (en) | 2020-06-02 | 2023-01-17 | Cilag Gmbh International | Staple cartridge |
USD975278S1 (en) | 2020-06-02 | 2023-01-10 | Cilag Gmbh International | Staple cartridge |
USD967421S1 (en) | 2020-06-02 | 2022-10-18 | Cilag Gmbh International | Staple cartridge |
USD976401S1 (en) | 2020-06-02 | 2023-01-24 | Cilag Gmbh International | Staple cartridge |
USD966512S1 (en) | 2020-06-02 | 2022-10-11 | Cilag Gmbh International | Staple cartridge |
US20220031351A1 (en) | 2020-07-28 | 2022-02-03 | Cilag Gmbh International | Surgical instruments with differential articulation joint arrangements for accommodating flexible actuators |
US11844518B2 (en) | 2020-10-29 | 2023-12-19 | Cilag Gmbh International | Method for operating a surgical instrument |
US11617577B2 (en) | 2020-10-29 | 2023-04-04 | Cilag Gmbh International | Surgical instrument comprising a sensor configured to sense whether an articulation drive of the surgical instrument is actuatable |
USD1013170S1 (en) | 2020-10-29 | 2024-01-30 | Cilag Gmbh International | Surgical instrument assembly |
US11931025B2 (en) | 2020-10-29 | 2024-03-19 | Cilag Gmbh International | Surgical instrument comprising a releasable closure drive lock |
USD980425S1 (en) | 2020-10-29 | 2023-03-07 | Cilag Gmbh International | Surgical instrument assembly |
US11517390B2 (en) | 2020-10-29 | 2022-12-06 | Cilag Gmbh International | Surgical instrument comprising a limited travel switch |
US11717289B2 (en) | 2020-10-29 | 2023-08-08 | Cilag Gmbh International | Surgical instrument comprising an indicator which indicates that an articulation drive is actuatable |
US11534259B2 (en) | 2020-10-29 | 2022-12-27 | Cilag Gmbh International | Surgical instrument comprising an articulation indicator |
US11896217B2 (en) | 2020-10-29 | 2024-02-13 | Cilag Gmbh International | Surgical instrument comprising an articulation lock |
US11779330B2 (en) | 2020-10-29 | 2023-10-10 | Cilag Gmbh International | Surgical instrument comprising a jaw alignment system |
US11452526B2 (en) | 2020-10-29 | 2022-09-27 | Cilag Gmbh International | Surgical instrument comprising a staged voltage regulation start-up system |
CN112358259A (en) * | 2020-11-27 | 2021-02-12 | 重庆水利电力职业技术学院 | Silicon-aluminum-based lightweight concrete material and preparation method thereof |
US11744581B2 (en) | 2020-12-02 | 2023-09-05 | Cilag Gmbh International | Powered surgical instruments with multi-phase tissue treatment |
US11627960B2 (en) | 2020-12-02 | 2023-04-18 | Cilag Gmbh International | Powered surgical instruments with smart reload with separately attachable exteriorly mounted wiring connections |
US11653915B2 (en) | 2020-12-02 | 2023-05-23 | Cilag Gmbh International | Surgical instruments with sled location detection and adjustment features |
US11849943B2 (en) | 2020-12-02 | 2023-12-26 | Cilag Gmbh International | Surgical instrument with cartridge release mechanisms |
US11678882B2 (en) | 2020-12-02 | 2023-06-20 | Cilag Gmbh International | Surgical instruments with interactive features to remedy incidental sled movements |
US11653920B2 (en) | 2020-12-02 | 2023-05-23 | Cilag Gmbh International | Powered surgical instruments with communication interfaces through sterile barrier |
US11944296B2 (en) | 2020-12-02 | 2024-04-02 | Cilag Gmbh International | Powered surgical instruments with external connectors |
US11737751B2 (en) | 2020-12-02 | 2023-08-29 | Cilag Gmbh International | Devices and methods of managing energy dissipated within sterile barriers of surgical instrument housings |
US11890010B2 (en) | 2020-12-02 | 2024-02-06 | Cllag GmbH International | Dual-sided reinforced reload for surgical instruments |
US11696757B2 (en) | 2021-02-26 | 2023-07-11 | Cilag Gmbh International | Monitoring of internal systems to detect and track cartridge motion status |
US11723657B2 (en) | 2021-02-26 | 2023-08-15 | Cilag Gmbh International | Adjustable communication based on available bandwidth and power capacity |
US11744583B2 (en) | 2021-02-26 | 2023-09-05 | Cilag Gmbh International | Distal communication array to tune frequency of RF systems |
US11701113B2 (en) | 2021-02-26 | 2023-07-18 | Cilag Gmbh International | Stapling instrument comprising a separate power antenna and a data transfer antenna |
US11749877B2 (en) | 2021-02-26 | 2023-09-05 | Cilag Gmbh International | Stapling instrument comprising a signal antenna |
US11751869B2 (en) | 2021-02-26 | 2023-09-12 | Cilag Gmbh International | Monitoring of multiple sensors over time to detect moving characteristics of tissue |
US11730473B2 (en) | 2021-02-26 | 2023-08-22 | Cilag Gmbh International | Monitoring of manufacturing life-cycle |
US11793514B2 (en) | 2021-02-26 | 2023-10-24 | Cilag Gmbh International | Staple cartridge comprising sensor array which may be embedded in cartridge body |
US11925349B2 (en) | 2021-02-26 | 2024-03-12 | Cilag Gmbh International | Adjustment to transfer parameters to improve available power |
US11812964B2 (en) | 2021-02-26 | 2023-11-14 | Cilag Gmbh International | Staple cartridge comprising a power management circuit |
US11826012B2 (en) | 2021-03-22 | 2023-11-28 | Cilag Gmbh International | Stapling instrument comprising a pulsed motor-driven firing rack |
US11759202B2 (en) | 2021-03-22 | 2023-09-19 | Cilag Gmbh International | Staple cartridge comprising an implantable layer |
US11717291B2 (en) | 2021-03-22 | 2023-08-08 | Cilag Gmbh International | Staple cartridge comprising staples configured to apply different tissue compression |
US11826042B2 (en) | 2021-03-22 | 2023-11-28 | Cilag Gmbh International | Surgical instrument comprising a firing drive including a selectable leverage mechanism |
US11737749B2 (en) | 2021-03-22 | 2023-08-29 | Cilag Gmbh International | Surgical stapling instrument comprising a retraction system |
US11806011B2 (en) | 2021-03-22 | 2023-11-07 | Cilag Gmbh International | Stapling instrument comprising tissue compression systems |
US11723658B2 (en) | 2021-03-22 | 2023-08-15 | Cilag Gmbh International | Staple cartridge comprising a firing lockout |
US11786243B2 (en) | 2021-03-24 | 2023-10-17 | Cilag Gmbh International | Firing members having flexible portions for adapting to a load during a surgical firing stroke |
US11849944B2 (en) | 2021-03-24 | 2023-12-26 | Cilag Gmbh International | Drivers for fastener cartridge assemblies having rotary drive screws |
US11944336B2 (en) | 2021-03-24 | 2024-04-02 | Cilag Gmbh International | Joint arrangements for multi-planar alignment and support of operational drive shafts in articulatable surgical instruments |
US11786239B2 (en) | 2021-03-24 | 2023-10-17 | Cilag Gmbh International | Surgical instrument articulation joint arrangements comprising multiple moving linkage features |
US11896219B2 (en) | 2021-03-24 | 2024-02-13 | Cilag Gmbh International | Mating features between drivers and underside of a cartridge deck |
US11793516B2 (en) | 2021-03-24 | 2023-10-24 | Cilag Gmbh International | Surgical staple cartridge comprising longitudinal support beam |
US11832816B2 (en) | 2021-03-24 | 2023-12-05 | Cilag Gmbh International | Surgical stapling assembly comprising nonplanar staples and planar staples |
US11903582B2 (en) | 2021-03-24 | 2024-02-20 | Cilag Gmbh International | Leveraging surfaces for cartridge installation |
US11744603B2 (en) | 2021-03-24 | 2023-09-05 | Cilag Gmbh International | Multi-axis pivot joints for surgical instruments and methods for manufacturing same |
US11849945B2 (en) | 2021-03-24 | 2023-12-26 | Cilag Gmbh International | Rotary-driven surgical stapling assembly comprising eccentrically driven firing member |
US11896218B2 (en) | 2021-03-24 | 2024-02-13 | Cilag Gmbh International | Method of using a powered stapling device |
US11857183B2 (en) | 2021-03-24 | 2024-01-02 | Cilag Gmbh International | Stapling assembly components having metal substrates and plastic bodies |
US11826047B2 (en) | 2021-05-28 | 2023-11-28 | Cilag Gmbh International | Stapling instrument comprising jaw mounts |
CN113426389B (en) * | 2021-08-13 | 2022-04-15 | 江南大学 | Preparation method of alcohol soluble protein microcapsule and product |
CN113756013A (en) * | 2021-09-14 | 2021-12-07 | 厦门数字智造工业研究院有限公司 | Nanofiber membrane with secondary pore structure and preparation method thereof |
US11877745B2 (en) | 2021-10-18 | 2024-01-23 | Cilag Gmbh International | Surgical stapling assembly having longitudinally-repeating staple leg clusters |
US11937816B2 (en) | 2021-10-28 | 2024-03-26 | Cilag Gmbh International | Electrical lead arrangements for surgical instruments |
CN115490891B (en) * | 2022-08-30 | 2024-03-08 | 新疆大学 | PVA/PDMS antibacterial hydrophobic membrane with three-level coarse structure and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060019264A1 (en) * | 2003-12-01 | 2006-01-26 | Said Attiya | Method for isolation of independent, parallel chemical micro-reactions using a porous filter |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4083741A (en) | 1975-12-15 | 1978-04-11 | Hoffmann-La Roche, Inc. | Novel dosage form |
US4818542A (en) * | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
JP2702953B2 (en) * | 1988-01-30 | 1998-01-26 | オリンパス光学工業株式会社 | Chemical impregnated ceramics |
US5456917A (en) | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
EP0896825B1 (en) * | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
GB2360789A (en) | 2000-03-30 | 2001-10-03 | Christopher Mason | Method of producing tissue structures |
AU2001261465A1 (en) * | 2000-05-12 | 2001-11-26 | The Regents Of The University Of Michigan | Reverse fabrication of porous materials |
US6730509B2 (en) | 2001-01-17 | 2004-05-04 | Bioverse, Inc. | Controlled release dispenser |
US20020122828A1 (en) * | 2001-03-02 | 2002-09-05 | Jun Liu | Hybrid porous materials for controlled release |
US6656506B1 (en) | 2001-05-09 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Microparticle coated medical device |
US6790455B2 (en) * | 2001-09-14 | 2004-09-14 | The Research Foundation At State University Of New York | Cell delivery system comprising a fibrous matrix and cells |
WO2003033580A2 (en) * | 2001-10-17 | 2003-04-24 | The Regents Of The University Of Michigan | Non-degradable and degradable porous materials with high surface areas |
AU2003218271A1 (en) * | 2002-04-18 | 2003-11-03 | Carnegie Mellon University | Method of manufacturing hydroxyapatite and uses therefor in delivery of nucleic acids |
-
2006
- 2006-04-25 US US11/410,480 patent/US8268344B2/en active Active
- 2006-04-25 WO PCT/US2006/015612 patent/WO2006116392A2/en active Application Filing
-
2012
- 2012-08-02 US US13/564,874 patent/US8568769B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060019264A1 (en) * | 2003-12-01 | 2006-01-26 | Said Attiya | Method for isolation of independent, parallel chemical micro-reactions using a porous filter |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008253558A (en) * | 2007-04-05 | 2008-10-23 | Olympus Corp | Production method of bioprosthesis |
WO2010104593A3 (en) * | 2009-03-13 | 2011-03-03 | President And Fellows Of Harvard College | Systems and methods of templating using particles such as colloidal particles |
CN102348499A (en) * | 2009-03-13 | 2012-02-08 | 哈佛学院院长等 | Systems and methods of templating using particles such as colloidal particles |
CN102327623A (en) * | 2011-09-21 | 2012-01-25 | 黑龙江大学 | Preparation method of DNA (deoxyribonucleic acid) vaccine nanoparticles containing PLGA (Poly-lactide-co-glycolide) for ND (necastle disease) |
EP3004324A4 (en) * | 2013-06-06 | 2017-01-04 | Sns Nano Fiber Technology, LLC | Three-dimensional structures for cell or tissue culture |
CN104414772A (en) * | 2013-09-06 | 2015-03-18 | 山东百多安医疗器械有限公司 | In-vivo degradable and absorbable artificial medical tissue repairing film |
US10272036B2 (en) | 2013-12-06 | 2019-04-30 | Intervet Inc. | Composition for oral delivery of bioactive agents |
US10806698B2 (en) | 2013-12-06 | 2020-10-20 | Intervet Inc. | Composition for oral delivery of bioactive agents |
CN104758261A (en) * | 2015-04-30 | 2015-07-08 | 中国医学科学院生物医学工程研究所 | Icariin PLGA nano particles and preparing method and application thereof |
CN108939136A (en) * | 2018-08-20 | 2018-12-07 | 重庆医科大学附属永川医院 | A kind of dressing and preparation method thereof for nose filling hemostasis |
CN108939136B (en) * | 2018-08-20 | 2020-12-22 | 重庆医科大学附属永川医院 | Dressing for nasal filling hemostasis and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US8568769B2 (en) | 2013-10-29 |
US20060246121A1 (en) | 2006-11-02 |
US20120301516A1 (en) | 2012-11-29 |
WO2006116392A3 (en) | 2007-02-08 |
US8268344B2 (en) | 2012-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8568769B2 (en) | Particle-containing complex porous materials | |
Chung et al. | Surface engineered and drug releasing pre-fabricated scaffolds for tissue engineering | |
Silva et al. | Materials in particulate form for tissue engineering. 1. Basic concepts | |
Dash et al. | Poly-є-caprolactone based formulations for drug delivery and tissue engineering: A review | |
Ju et al. | Extracellular vesicle-loaded hydrogels for tissue repair and regeneration | |
Wei et al. | Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB | |
Wang et al. | Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineering | |
KR101302557B1 (en) | Method For Preparing Polymeric Biomaterials Having Immobilized Drug Delivery System Comprising Bioactive Molecules Loaded Particulate Carrier | |
Liao et al. | Controlled release from fibers of polyelectrolyte complexes | |
Jaklenec et al. | Novel scaffolds fabricated from protein-loaded microspheres for tissue engineering | |
Hu et al. | Biomimetic fabrication of icariin loaded nano hydroxyapatite reinforced bioactive porous scaffolds for bone regeneration | |
Hu et al. | Nano-fibrous tissue engineering scaffolds capable of growth factor delivery | |
US20110263018A1 (en) | Core-shell structured delivery system for growth factors, a preparation method thereof, and use thereof for the differentiation or proliferation of cells | |
Ashammakhi et al. | Advancing tissue engineering by using electrospun nanofibers | |
Kerimoglu et al. | Poly (lactic-co-glycolic acid) based drug delivery devices for tissue engineering and regenerative medicine | |
Batista et al. | Alginate: Pharmaceutical and medical applications | |
EP2793962B1 (en) | Process for modifying the surface morphology of a medical device | |
Li et al. | Functional microspheres for tissue regeneration | |
Patel et al. | Potential application of PLGA microsphere for tissue engineering | |
Zhang | Injectable biomaterials for stem cell delivery and tissue regeneration | |
US11213490B2 (en) | Encapsulation-free controlled protein release system | |
Demirtaş et al. | Combined delivery of PDGF-BB and BMP-6 for enhanced osteoblastic differentiation | |
KR101277658B1 (en) | Method of preparing biomedical ceramic materials comprising multi-drug delivery system | |
Mohan et al. | Incorporation of human-platelet-derived growth factor-BB encapsulated poly (lactic-co-glycolic acid) microspheres into 3D CORAGRAF enhances osteogenic differentiation of mesenchymal stromal cells | |
Chew et al. | Bioresorbable polymer microparticles in the medical and pharmaceutical fields |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06769885 Country of ref document: EP Kind code of ref document: A2 |